预约演示
更新于：2026-08-15
Respiratory Syncytial Virus Vaccine(Moderna)
更新于：2026-08-15
概要
基本信息
药物类型 预防性疫苗、mRNA疫苗 |
别名 Respiratory Syncytial Virus (RSV) pre-fusion F protein (Moderna)、Respiratory syncytial virus (RSV) vaccine (Moderna)、mRNA 1345 + [4] |
作用方式 调节剂 |
作用机制 Respiratory syncytial virus F protein调节剂(呼吸道合胞病毒F蛋白调节剂) |
非在研适应症- |
原研机构 |
非在研机构- |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 美国 (2024-05-30), |
最高研发阶段(中国)- |
特殊审评快速通道 (美国)、优先审评 (澳大利亚)、突破性疗法 (美国) |
登录后查看时间轴
结构/序列
Sequence Code 1375149713
来源: *****
关联
15
项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的临床试验NCT07185399
Systems Biological Analysis of Immune Responses to RSV Vaccine
The purpose of this study is to characterize the immune response to the FDA-approved mRNA-based RSV vaccine in adults ≥60 years of age, using a systems biology approach. The study aims to generate high-resolution immunologic and systems biology data following vaccination to identify early biomarkers of response and gain mechanistic insight into host immunity.
开始日期2025-10-13 |
申办/合作机构  Emory University [+1] |
NCT07117487
A Phase 3 Open-label Study to Evaluate Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345 at Least 12 Months Following a Primary Dose of a Licensed Protein Subunit RSV Vaccine in Adult Participants ≥60 Years of Age
The purpose of this study is to evaluate safety, tolerability and immunogenicity of mRNA-1345 in participants who have been previously vaccinated with either Arexvy or Abrysvo at least 12 months prior to enrollment, are medically stable and aged ≥60 years.
开始日期2025-08-05 |
申办/合作机构 |
NCT06143046
A Phase 2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Reactogenicity, Safety, and Immunogenicity of mRNA-1345, an mRNA Vaccine Targeting Respiratory Syncytial Virus, in Pregnant Women, and Safety and Immunogenicity in Infants Born to Vaccinated Mothers
The purpose of the study is to evaluate the reactogenicity, safety, and immunogenicity of an investigational respiratory syncytial virus (RSV) vaccine, mRNA-1345, in pregnant women, and safety and immunogenicity in infants born to vaccinated mothers.
开始日期2023-11-15 |
申办/合作机构 |
100 项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的临床结果
登录后查看更多信息
100 项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的转化医学
登录后查看更多信息
100 项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的专利（医药）
登录后查看更多信息
39
项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的文献（医药）2026-12-01·Human Vaccines & Immunotherapeutics
Coadministration of mRNA-1345 RSV vaccine with high-dose quadrivalent influenza vaccine in adults aged 65 and older: An observer-blinded, placebo-controlled, randomized, phase 3 trial.
Article
作者: Fogarty, Charles ; Rushton, Lee ; Comstock, Emily ; Caso, Jorge ; Sinha, Ambrish ; Vu, Jack ; Ma, Chong ; Chen, HuiLing ; Cao, Xin ; Priddy, Frances
Coadministration of respiratory syncytial virus (RSV) and seasonal influenza vaccines can increase vaccination uptake. mRNA-1345 (mRESVIA, Moderna, Inc.) is indicated in multiple countries for prevention of RSV-lower respiratory tract disease in adults. This randomized, observer-blind, phase 3 study evaluated safety, tolerability, immunogenicity, and inferred efficacy of mRNA-1345 when coadministered with quadrivalent influenza vaccine-high dose (QIV-HD). Adults ≥65 y (n = 1900) were randomly assigned 1:1 to receive both vaccines coadministered at day 1 or sequentially, 21 d apart. Noninferiority of six co-primary immunogenicity endpoints was assessed up to 21 d post vaccination, comparing coadministered versus sequential vaccination. Immunogenicity was measured by serum-neutralizing antibody responses and seroresponse rates for RSV or seroconversion rate for influenza. Reactogenicity was mild/moderate and there were no safety concerns, related serious adverse events, or deaths. Noninferiority of immune responses against influenza A (H1N1, H3N2) and B (Austria, Phuket) was demonstrated, with geometric mean ratios (GMRs; coadministration vs sequential vaccination) of anti-hemagglutinin titers ranging from 0.868-0.948. All lower bounds of the corresponding 95% CI were >0.667, consistent with the commonly accepted noninferiority margin of 1.5 (i.e. 0.667 = 1/1.5). Noninferiority against RSV-A and RSV-B based on GMR was not demonstrated; GMRs (95% CI) of neutralizing antibody were 0.625 (0.570-0.686) and 0.638 (0.584-0.697) for RSV-A and RSV-B, respectively, with the lower bound of 95% CI < 0.667 for RSV-A and B. Coadminstration is estimated to maintain the efficacy of mRNA-1345 against RSV-lower respiratory tract disease based on a correlate of protection model. These results support coadministration of mRNA-1345 with QIV-HD.Clinical trials registration: ClinicalTrials.gov: NCT06060457.
2026-08-01·VACCINE
Adverse events and vaccine administration errors following RSV vaccination: Findings from the United States VAERS database, 2023–2025
Article
作者: Ezeala, Oluchukwu M ; Westrick, Salisa C ; Qian, Jingjing ; Ezeja, Lotanna
INTRODUCTION:
Three respiratory syncytial virus (RSV) vaccines are marketed in the U.S. for use in adults aged ≥18 years: Arexvy® (GSK), Abrysvo® (Pfizer), and mRESVIA® (Moderna), with only Abrysvo® approved for use during pregnancy. This study describes post-marketing adverse event (AE) reports after RSV vaccination and detected reporting risk signals of administration-related errors using the U.S. Vaccine Adverse Event Reporting System (VAERS).
METHODS:
We searched the VAERS database for reports of AE following RSV vaccination during January 1, 2023 - December 31, 2025. We assessed the characteristics of these reports and described the most commonly reported AEs by RSV vaccine brand. The top 15 most frequently reported AEs and top 10 most frequently reported vaccine administration errors were examined for Arexvy® and Abrysvo®. Disproportionality analyses (reporting odds ratio) were conducted to detect disproportionate reporting risk signals of vaccine administration errors (SAS version 9.4).
RESULTS:
During the study period, VAERS received 8365 AE reports following RSV vaccination; most were after Arexvy® (68.2%) and Abrysvo® (29.9%). The 5 most frequently reported AEs for Arexvy® were extra dose administered (15.0%), injection site pain (12.8%), injection site erythema (11.3%), injection site swelling (9.0%), and pain (9.0%); while for Abrysvo®, they included exposure during pregnancy (10.6%), extra dose administered (9.9%), headache (7.7%), fatigue (7.7%) and injection site pain (7.3%). Although not recommended for use during the study period, 4.2% (n = 244) of reports after Arexvy® vaccination were from individuals <50 years old; 6.6% (n = 375) were exposure during pregnancy. Both Arexvy® and Abrysvo® exhibited significant signals for vaccine administration errors such as extra dose administered and product administered to patient of inappropriate age.
CONCLUSIONS:
Most AE reports following RSV vaccination were non-serious. The potential misuse of Arexvy® during pregnancy and excess dose for both Arexvy® and Abrysvo® highlight potential gaps in healthcare provider education and vaccine record retrieval.
2026-05-01·JOURNAL OF THE AMERICAN PHARMACISTS ASSOCIATION
Protecting the vulnerable: Narrative review on RSV vaccines in adults and pregnancy
Review
作者: Zaed, Mohammed ; Bullers, Krystal ; Tabulov, Christine E. ; Shaeer, Kristy M.
BACKGROUND:
Recent years have seen substantial advances in the prevention of respiratory syncytial virus (RSV) lower respiratory tract disease (LRTD) among adults and pregnant individuals. Three RSV vaccines have been licensed for adults, one of which is also authorized during pregnancy.
OBJECTIVES:
To provide the first pharmacist-centered narrative review of the efficacy, immunogenicity, and safety data for 3 novel RSV vaccines; to summarize early postmarketing surveillance findings that prompted labeling updates; and to offer practical guidance for pharmacists to support vaccine uptake among adult and pregnant populations.
METHODS:
A narrative review was conducted following PRISMA-ScR principles. MEDLINE, Web of Science, and Embase were searched for English-language studies published from January 2022 through June 2025 to capture pivotal phase 2 and 3 trial data for licensed RSV vaccines. Additional data were obtained from regulatory documents, clinical trial registries, and Centers for Disease Control and manufacturer websites. Eligible studies evaluated the safety, immunogenicity, or efficacy of RSVPreF3 OA, RSVpreF, or mRNA-1345 in adults or pregnant individuals. Data were extracted by 2 reviewers and synthesized descriptively. Although no formal risk-of-bias tool was applied due to heterogeneous study designs, study quality elements were qualitatively considered during interpretation.
RESULTS:
Three vaccines demonstrated efficacy, immunogenicity, and safety in preventing RSV-LRTD in adults. One vaccine is FDA-licensed for maternal RSV vaccination during pregnancy and confers protection against RSV respiratory disease in infants. Vaccine selection in adults may be influenced by comparative efficacy, comorbid conditions, and side-effect profiles.
CONCLUSION:
This review summarizes current evidence supporting licensed RSV vaccines, including early postmarketing safety findings, and underscores the role of pharmacists in addressing gaps in RSV vaccine equity. Recent RSV vaccine licensure provides a novel strategy to mitigate disease severity, with pharmacists well positioned to educate patients and support informed vaccination decisions.
457
项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的新闻（医药）2026-08-14
Moderna (MRNA) 股票专业分析报告 - 海螺财经指数模型
分析股票： Moderna (MRNA)
分析基准： S&P 500
分析日期： 2026-08-10
目标投资周期： 中期 (MEDIUM)一、基本面分析
1. 财务健康度：
Moderna在2026年第二季度报告中，营收为1.45亿美元，略高于2025年同期的1.42亿美元，同比增长2.1%。然而，公司仍处于亏损状态，GAAP净亏损为8亿美元，每股亏损(EPS)为1.97美元，尽管较2025年第二季度的2.13美元有所改善。公司预计2026年全年营收将实现高达10%的增长。运营费用方面，2026年第二季度销售成本下降22%至9300万美元，研发费用下降7%至6.51亿美元，销售、管理和行政费用下降6%至2.16亿美元，显示出公司在控制成本方面的努力。截至2026年6月30日，Moderna的现金、现金等价物和投资为69亿美元，预计2026年底现金余额将改善至47亿至52亿美元。公司的速动比率为2.18，流动比率为2.29，债务股本比为0.09，显示出较强的偿债能力和充足的流动性。然而，持续的净亏损和高额研发投入导致现金持续消耗，2025财年运营现金流出18.73亿美元。
结论与评分： 6.5分。尽管拥有充足的现金和良好的偿债能力，但持续的亏损和现金消耗限制了财务健康度的评分，未来盈利能力仍是关键挑战。
2. 成长性与估值：
分析师对Moderna的估值普遍持谨慎态度。根据DCF模型，Moderna的内在价值远低于当前市场价格，例如有模型估算其内在价值为11.91美元（当前市场价55.45美元时，被高估79%）或24.32美元（当前市场价56.26美元时，被高估131.3%）。由于公司持续亏损，市盈率(P/E)为负值，因此不适用。市销率(P/S)高达10.01，显著高于其历史中位数约8.3倍及行业平均水平，反映出市场对其未来增长的较高预期。分析师对Moderna的共识评级多为“持有”或“减持”，平均目标价在42.13美元至52.63美元之间，普遍低于当前股价。
结论与评分： 4.0分。多项估值模型显示公司当前股价被高估，且分析师普遍持谨慎态度，成长性虽然存在但估值已充分反映。
3. 护城河与前景：
Moderna的核心护城河在于其领先的mRNA技术平台和广泛的专利组合。公司已成功将mRNA技术应用于COVID-19疫苗，并正在拓展至流感、RSV、癌症和罕见病等领域。最近的关键催化剂是其季节性流感疫苗mFLUSIVA于2026年8月5日获得FDA批准，这是其第四款获批疫苗，为公司开辟了新的大型市场。此外，mRESVIA和mNEXSPIKE也获得多个市场的监管批准。公司还在推进个性化癌症疫苗（与默克合作）和罕见病项目。然而，竞争格局激烈，主要竞争对手包括辉瑞/BioNTech、葛兰素史克(GSK)等。mRNA-1403诺如病毒疫苗三期中期分析未达早期成功统计标准，显示出研发的固有风险。专利诉讼（如与BioNTech/Acuitas/Pfizer的mRNA-LNP专利纠纷）也可能影响未来的市场准入和特许权使用费。
结论与评分： 7.5分。强大的技术平台和不断扩大的产品线是核心优势，但激烈的竞争和研发失败风险不容忽视。二、技术分析
1. 趋势研判：
截至2026年8月8日，Moderna股价约为59.17美元。近期（中期）走势显示，股价已跌破上升趋势通道的底部，预示着上涨动能减弱。短期来看，股价已跌破58.00美元的支撑位，发出短期交易区间的负面信号，预计将进一步下跌。长线来看，虽然股价较2021年497.49美元的历史高点大幅回落，但在过去一年中（截至2026年8月7日）上涨了125.70%，显示出在大幅回调后的反弹潜力，但近期趋势转弱。
结论与评分： 5.0分。中期趋势转弱，短期跌破关键支撑，但长期仍有从低位反弹的弹性，趋势复杂。
2. 关键价位：
核心支撑位在58.00美元已被跌破，该点位现在转变为短期阻力位。从历史数据看，52周低点为22.28美元，52周高点为85.60美元。近期（7月初）曾触及85.60美元的高点后回调35%。
结论与评分： 6.0分。支撑位被跌破，表明下行风险增加，但历史高低点提供了清晰的波动区间。
3. 指标信号：
* 移动平均线 (MA/EMA): 股价低于其5日、20日和50日指数移动平均线(EMA)和简单移动平均线(SMA)，表明当前趋势强烈看跌，存在卖压。然而，200日简单移动平均线（52.99美元或45.43美元）通常显示为买入信号，可能反映了长期底部支撑。
* RSI (14): 截至2026年8月6日，RSI低于30，表明股票处于超卖状态，具有强烈的负面动量。然而，在大型股票中，超卖也可能预示着价格即将反弹。截至8月7日，RSI为36.92，处于中性区域。RSI曲线呈下降趋势，可能是价格开始下跌趋势的早期信号。
* MACD (12,26): 存在矛盾数据，有报告显示MACD为-45.04（买入信号），另有报告显示为-2.13（卖出信号）。鉴于移动平均线和RSI的整体看跌或中性信号，MACD的负值通常支持偏弱的趋势。
* 成交量: 成交量顶部和底部与价格顶部和底部吻合，这削弱了趋势突破的强度。
结论与评分： 4.5分。多数技术指标显示短期看跌压力，RSI超卖可能预示反弹，但整体动能偏弱。三、现代投资组合理论分析
1. 风险收益特征：
Moderna的β系数存在较大差异，有报告显示为0.91，也有1.45，甚至2.02。考虑到其作为高增长生物科技公司的特性和历史波动性，采用1.45作为其相对于S&P 500市场的波动性衡量更为合理。这意味着Moderna的股价波动性高于市场平均水平。
结论与评分： 7.0分。高β系数表明其风险收益特征为高波动、高风险，可能带来超额收益，但也伴随较大下行风险。
2. 组合角色：
Moderna作为一支高波动性的生物科技股，在多元化投资组合中可以扮演增长型资产的角色。其潜在的“阿尔法”收益（如果成功商业化新药）可以提升组合的整体回报。然而，其与市场（S&P 500）的正相关性（虽然具体相关性数据未直接提供，但高β已暗示）意味着其在市场下跌时可能无法提供很好的对冲效果。夏普比率等风险调整后收益指标未直接提供，但考虑到其高波动性，其风险调整后收益可能不会特别突出，除非有显著的超额回报。
结论与评分： 6.5分。可作为组合的增长引擎，但高波动性限制了其多元化效应，不适合作为防御性资产。
3. 风险分解：
Moderna的风险可以分解为系统性风险和非系统性风险。高β系数（1.45）表明其受市场整体波动影响较大，存在显著的系统性风险。非系统性风险主要来源于公司特定的因素，如研发成功率（诺如病毒疫苗的挫折）、监管审批（mFLUSIVA的批准）、专利诉讼、新产品商业化能力、以及对少数产品的依赖（如COVID-19疫苗需求下降后的转型）。生物科技行业的固有风险使得非系统性风险在其总风险中占有较大比重。
结论与评分： 7.5分。系统性风险和非系统性风险均较高，其中非系统性风险因其研发驱动型业务模式而尤为突出。四、有效市场假说检验
1. 信息效率：
Moderna股价对公开信息的反应通常迅速。例如，mFLUSIVA获得FDA批准的消息发布后，股价在盘初有所上涨，但随后回落，这表明市场在一定程度上已经消化了这一利好，或者有其他负面因素（如谨慎的营收指引或持续亏损）抵消了部分乐观情绪。这暗示市场可能达到了半强式有效，即公开信息能较快反映在股价中。
结论与评分： 6.0分。股价对公开信息反应迅速，但市场情绪和长期基本面因素可能导致短期波动后回归理性。
2. 异常检测：
从目前可得的信息来看，没有明显的、可被持续利用的定价错误或市场异象。虽然有分析指出，Moderna股价在触及某个历史看涨趋势线时，在过去有82%的胜率并在一个月内平均上涨68%的“买入信号”，但这可能受到2020-2021年疫情期间异常涨幅的强烈影响，难以视为可持续的异象。
结论与评分： 5.0分。没有明确证据表明存在可利用的长期市场异象。
3. 内幕信号：
在过去24个月内，Moderna内部人存在大量股票出售行为，总计出售315,302股，价值超过1500万美元。其中，CEO Stéphane Bancel在2026年8月5日至6日行使了大量期权并出售部分股票以支付行权成本和税费，这是根据预先设定的10b5-1交易计划执行的。其他高管也报告了出售股票。虽然10b5-1计划的交易是预先安排的，不直接反映当前市场情绪，但持续的内部人卖出（即使是行权后出售）通常被市场解读为偏向负面信号，或至少表明内部人认为现有股价已反映部分价值，没有显著低估。
结论与评分： 4.0分。内部人持续出售股票，即使部分通过10b5-1计划，也表明内部人对未来股价的乐观程度有限。五、资本资产定价模型分析
1. 预期收益率：
使用CAPM模型计算Moderna的理论预期收益率：
* 无风险利率 (Rf)：采用美国10年期国债收益率，截至2026年8月10日为4.67%。
* 市场风险溢价 (Rm - Rf)：通常取5.5% (历史平均值)。
* Beta (β)：采用1.45。
预期收益率 = Rf + β * (Rm - Rf) = 4.67% + 1.45 * 5.5% = 4.67% + 7.975% = 12.645%
结论与评分： 6.0分。基于CAPM模型，Moderna的理论预期收益率为12.645%，高于无风险利率，反映了其较高的风险溢价要求。
2. 阿尔法评估：
Moderna在过去12个月内实现了111%的显著收益，远超S&P 500的21%增长。这表明其在特定时期内产生了巨大的超额收益（正阿尔法）。然而，这种超额收益主要受疫情期间的特殊需求和mRNA技术突破的早期红利驱动。在后疫情时代，随着市场对新产品的审视和竞争加剧，维持高额阿尔法将面临挑战。当前的分析师目标价普遍低于现价，暗示未来一年可能难以持续产生显著的正阿尔法。
结论与评分： 7.0分。历史表现曾显示显著超额收益，但未来能否持续产生正阿尔法存在不确定性，需要新的催化剂。六、套利定价理论分析
1. 因子暴露：
Moderna的股价主要暴露于以下几个因子：
* 研发成功因子： 生物科技公司最核心的驱动力，临床试验结果和监管审批是股价的重大催化剂（如mFLUSIVA的批准）。
* 行业竞争因子： 来自辉瑞/BioNTech、GSK等竞争对手的产品开发和市场份额争夺对其营收和利润有直接影响。
* 宏观经济利率因子： 作为一家高成长、高研发投入且目前尚未盈利的公司，其估值对利率变化较为敏感。利率上升会提高未来现金流的折现率，对其估值产生负面影响。
* 公共卫生政策因子： 疫苗需求和政府采购政策对其收入有重要影响，尤其是COVID-19疫苗需求正常化后，季节性流感和RSV疫苗的市场推广至关重要。
结论与评分： 7.0分。主要受研发成功、行业竞争和利率等核心因子驱动，对这些因子的敏感度较高。
2. 敏感度分析：
* 积极情景： 若Moderna的肿瘤疫苗（如黑色素瘤疫苗）或罕见病药物在2026年获得积极临床数据或监管突破，且mFLUSIVA和mRESVIA的市场渗透率超出预期，公司有望实现盈利并加速增长，股价将大幅上涨。
* 中性情景： 现有产品线稳定增长，但新药研发进展符合预期但无重大惊喜，或面临激烈的市场竞争导致增长放缓，股价可能在当前水平附近震荡或小幅波动。
* 消极情景： 若关键临床试验失败（如诺如病毒疫苗），或专利诉讼出现不利结果，或市场对mRNA疫苗的接受度因政策（如RFK Jr.的质疑）或负面新闻而下降，将对其营收和市场情绪造成严重打击，股价可能大幅下挫。
结论与评分： 7.0分。公司股价对研发进展和市场接受度具有高敏感性，表现出较强的弹性，但下行风险也同样显著。七、行为金融学分析
1. 市场情绪：
市场对Moderna的情绪呈现两极分化。一方面，分析师普遍持“持有”或“减持”的谨慎立场，平均目标价低于当前股价。另一方面，有新闻和博客观点在8月初显示“非常看涨”或“看涨”的积极情绪。Forbes也指出，尽管股价在FDA批准流感疫苗后有所回落，但其正在测试一个历史上看涨的趋势线，且存在大量空头头寸（14.3%的流通股被做空），可能引发轧空。期权交易者则普遍看跌，表现为较高的看跌/看涨期权比率。这种复杂的情绪反映了投资者对公司长期潜力和近期财务表现的权衡。
结论与评分： 5.0分。市场情绪复杂且两极分化，存在过度悲观和过度乐观并存的现象。
2. 认知偏差：
* 锚定效应： 投资者可能仍会锚定Moderna在疫情高峰期497美元的历史高点，导致对当前股价的看法出现偏差，或期望过高的反弹。
* 过度反应/反应不足： FDA批准流感疫苗的消息发布后，股价先涨后跌，可能反映了市场对利好消息的短期过度反应，随后又因公司持续亏损和谨慎指引而修正。
* 羊群效应： 生物科技板块的炒作性质可能导致投资者在利好消息出现时盲目跟风买入，或在负面消息出现时恐慌性抛售，尤其是在缺乏深入基本面分析的情况下。
* 处置效应： 投资者可能倾向于过早卖出盈利的股票（锁定利润），而持有亏损的股票（不愿承认损失），这在Moderna股价大幅波动时尤为明显。
结论与评分： 4.0分。投资者可能受到锚定效应、过度反应和羊群效应等认知偏差的影响，导致股价波动加剧。八、因子投资分析
1. 因子诊断：
* 成长因子： Moderna具有显著的成长因子暴露。公司专注于高增长的mRNA技术平台，拥有丰富的研发管线，旨在开发突破性疫苗和疗法。营收增长潜力（预计2026年高达10%增长）是其核心驱动力。
* 质量因子： 鉴于公司目前处于持续亏损状态，且自由现金流为负，其在盈利能力方面的质量因子暴露较低。然而，其强大的资产负债表和充足的现金储备在一定程度上提升了其财务稳健性。
* 动量因子： 在过去12个月内，Moderna股价表现出强劲的动量，上涨了111%。然而，近期股价从高点回调，短期动量有所减弱。
* 价值因子： 由于公司目前无盈利且估值偏高（高P/S比），其价值因子暴露较低。
* 规模因子： Moderna市值约224.6亿至236.2亿美元，属于中大型生物科技公司，规模因子暴露适中。
结论与评分： 7.0分。主要暴露于成长和动量因子，质量和价值因子暴露较低。
2. 风格评估：
Moderna的核心投资风格是成长型 (Growth)。其股价主要由未来研发成功、新产品商业化潜力和市场份额扩张等预期驱动。公司需要通过持续的研发投入和创新来维持其成长性。在经历了疫情期间的爆发式增长后，其风格正从“超高增长”回归到“高风险高回报的生物科技成长股”。
结论与评分： 6.5分。典型的成长型股票，未来业绩取决于研发管线的成功转化和商业化能力。九、风险管理分析
1. 风险量化：
* 历史波动率： Moderna的股价波动性较高。30天历史波动率（收盘价对收盘价）在2026年8月4日为0.6788。TradingView报告其波动率为10.17%。Macroaxis报告其90天实际波动率为4.67%。
* VaR (Value at Risk): 未直接提供，但根据其高波动率，其VaR值将相对较高，表明在给定置信水平下，潜在损失较大。
* 最大回撤 (Maximum Drawdown): Moderna的历史最大回撤高达95.38%（发生在2025年11月19日），目前仍处于87.24%的回撤中。这表明该股票在极端情况下可能遭受巨大损失。
结论与评分： 4.0分。历史波动率和最大回撤均极高，显示出巨大的下行风险。
2. 压力测试：
在最坏情景下，Moderna可能面临以下跌幅：
* 临床试验重大失败： 如果其核心的肿瘤或罕见病管线（如mRNA-4157或针对丙酸血症的项目）出现重大挫折或未能获得批准，将对其长期增长前景构成毁灭性打击，股价可能跌至DCF模型所示的极低估值区间（如10-25美元），甚至更低。
* 专利诉讼失利： 若在与辉瑞/BioNTech等公司的LNP专利纠纷中败诉，可能面临巨额赔偿或丧失核心技术授权，严重影响其商业模式和营收，股价可能大幅跳水。
* 市场竞争加剧/需求不及预期： 如果mFLUSIVA和mRESVIA的市场渗透率低于预期，或面临更强劲的竞争，导致营收增长乏力，且公司无法在2028年实现现金流盈亏平衡的目标，投资者信心可能崩塌，股价可能跌回52周低点附近（22.28美元）甚至更低。
结论与评分： 4.5分。在极端负面事件冲击下，Moderna面临极高的潜在跌幅，可能导致投资者资产大幅缩水。十、中期（3个月）操作建议
基于上述所有分析，特别是技术分析、行为金融学和风险管理结论，Moderna短期内面临较大的不确定性和下行压力，尽管长期潜力依然存在。
* 目标价格： 65.00美元
* 止盈价格： 62.00美元（第一批），65.00美元（第二批）
* 止损价格： 50.00美元
* 当前股价与趋势： Moderna当前股价在59.17美元附近，短期已跌破58.00美元支撑位，且多数短期移动平均线均发出卖出信号，RSI超卖但MACD信号矛盾，表明短期下行压力较大。
* 行为金融学考量： 尽管分析师普遍谨慎，但新闻和博客情绪仍有看涨倾向，且存在空头回补的潜力（14.3%的空头头寸）。Forbes提及的“买入信号”虽然历史数据受疫情影响，但仍提示了短期反弹的可能性。FDA批准流感疫苗是利好，但市场需要时间消化和观察商业化表现。
* 风险管理： 考虑到其极高的历史波动率和最大回撤，止损位设置在50.00美元，旨在限制潜在损失。50美元是近期关键心理支撑位，一旦跌破可能进一步加速下跌。
* 中期目标： 65.00美元的目标价是基于短期超卖反弹以及对mFLUSIVA商业化初期乐观预期的合理区间。若能成功触发空头回补，结合利好消息的滞后效应，股价有机会回升至此前高点85.60美元的35%回调位附近。止盈价格分批设置，以应对股价波动性，确保部分收益。
* 风险说明：
1. 研发及商业化风险： 若mFLUSIVA商业化不及预期，或肿瘤/罕见病管线进展缓慢甚至失败，将直接影响股价。
2. 市场情绪反转： 当前市场情绪复杂，若悲观情绪占据主导，或宏观经济环境恶化，股价可能继续下行，止损位可能被触发。
3. 竞争加剧： 竞争对手推出更有效或更便宜的产品，可能侵蚀Moderna的市场份额。
4. 估值过高： 即使短期反弹，公司基本面估值仍显高估，长期可持续性有待观察。十一、最终综合报告与策略建议
1. 多空观点汇总：
2. 总体评级： 持有
Moderna拥有强大的mRNA技术平台和不断拓展的研发管线，流感疫苗的成功获批是重要的里程碑，为其未来增长提供了新的动力。然而，公司目前仍处于亏损状态，现金持续消耗，且现有估值已显著反映了未来的增长预期，甚至被多项模型判定为高估。技术面上，短期趋势偏弱，但超卖状态和空头回补潜力可能带来短期反弹。鉴于其高波动性和显著的研发及商业化风险，对于新投资者而言，目前并非“买入”的理想时机；对于已持有者，建议“持有”并密切关注关键催化剂和风险事件。
3. 投资策略：
* 激进型投资者： 可考虑在股价触及50-52美元区间并出现止跌信号时，进行小仓位试探性买入，博取短期反弹和空头回补收益，但必须严格设置止损（如跌破48美元）。仓位不宜过重，并准备好应对高波动。
* 稳健型投资者： 建议观望，等待公司实现盈利或现金流转正的明确信号，或者等待股价回调至更具吸引力的估值区间（例如30-40美元），以降低风险。
* 保守型投资者： 强烈不建议投资Moderna。其高风险、高波动性和不确定性不符合保守型投资者的风险偏好。
4. 核心风险提示：
1. 研发管线失败与商业化不及预期： 关键在研药物的临床试验结果和监管审批存在不确定性，已获批疫苗的市场接受度及销售额可能不及预期，直接影响公司未来盈利能力。
2. 估值过高与盈利压力： 当前股价已充分甚至过度反映未来增长预期，但公司持续亏损且现金消耗较大，若无法在预期时间内实现盈利，股价将面临巨大调整压力。
3. 市场竞争与知识产权风险： mRNA技术领域竞争激烈，且存在多起专利诉讼，任何不利判决或竞争对手的突破都可能削弱Moderna的竞争优势。
投资免责声明
本报告由海螺财经社（Hailuo Finance）量化分析系统自动生成。报告内容仅供参考，不构成任何投资建议、要约或要约邀请。
1. 数据来源：本报告基于公开市场数据和互联网信息进行分析，海螺财经社力求但不保证数据的准确性、完整性和及时性。
2. 模型局限：海螺财经指数模型基于既定算法运行，可能无法完全涵盖所有市场因素，极端行情下可能失效。
3. 风险提示：投资有风险，入市需谨慎。投资者应根据自身风险承受能力独立做出投资决策，海螺财经社不对因使用本报告内容而导致的任何损失承担法律责任。参考文献与数据来源
2026-08-09
Clinical Infectious Diseases Volume 82 Issue 1
临床传染病学 82卷1期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病学技艺）
1
Peasants' Revolt, 1381
1381年农民起义
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page i, https://doi.org/10.1093/cid/ciaf692
In the Literature（文献概览）
2
In the Literature
文献概览
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages ii–iii, https://doi.org/10.1093/cid/ciaf631
State-of-the-Art Review（最新技术综述）
3
State-of-the-Art Review: Diagnosis and Management of Acute and Chronic Bacterial Prostatitis
最新技术综述：急性和慢性细菌性前列腺炎的诊断与治疗
Prathit A Kulkarni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 1–13, https://doi.org/10.1093/cid/ciaf483
Clinical Dilemmas in Infectious Diseases（传染病临床难题）
4
“Insisting on Treatment”
“坚持治疗”
Kevin Andrew Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 14–18, https://doi.org/10.1093/cid/ciaf282
Voices of ID（传染病之声）
5
Martin Arrowsmith and Me
马丁·阿罗史密斯与我
Janet R Gilsdorf
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 19–20, https://doi.org/10.1093/cid/ciaf277
Invited Commentary（特邀述评）
6
The 2025 Centers for Disease Control and Prevention Nonoccupational HIV Postexposure Prophylaxis Guidelines: Updated Regimens and Remaining Questions
2025年美国疾病控制与预防中心非职业性艾滋病毒暴露后预防指南：更新方案及遗留问题
Lao-Tzu Allan-Blitz and Kenneth H Mayer
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 21–24, https://doi.org/10.1093/cid/ciaf567
Antimicrobial Resistance and Stewardship（抗菌药物耐药性与管控）
7
Modeling the Impact and Cost of a Culture-Dependent Molecular Test for Antimicrobial Resistance in Resource-Limited Settings
资源有限环境下，基于培养的分子检测法对抗菌药物耐药性的影响和成本建模
Joshua M Chevalier and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 25–32, https://doi.org/10.1093/cid/ciaf236
8
The Xpert MTB/RIF Cycle Threshold Value Predicts Mycobacterium tuberculosis Transmission to Close Contacts in a Brazilian Prospective Multicenter Cohort
巴西一项前瞻性多中心队列研究中Xpert MTB/RIF循环阈值可预测结核分枝杆菌在密切接触者中的传播
Leandro S Garcia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 33–41, https://doi.org/10.1093/cid/ciad794
9
Beyond Diagnosis: Xpert Cycle Threshold Values as Predictors of Tuberculosis Transmission
超越诊断：Xpert循环阈值作为结核病传播的预测指标
Lauren Linde and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 42–43, https://doi.org/10.1093/cid/ciad791
10
First Report of Treatment-Emergent Resistance to Cefepime-Zidebactam in Pseudomonas aeruginosa
铜绿假单胞菌在头孢吡肟-齐德巴坦治疗中出现耐药性的首例报告
Ava J Dorazio and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 44–48, https://doi.org/10.1093/cid/ciaf638
Clinical Practice and Policy（临床实践与政策）
11
Sputum and Tongue Swab Molecular Testing for the In-Home Diagnosis of Tuberculosis in Unselected Household Contacts: A Cost and Cost-Effectiveness Analysis
痰液和舌拭子分子检测用于未筛选家庭接触者结核病居家诊断的成本及成本效益分析
Charl Bezuidenhout and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 49–57, https://doi.org/10.1093/cid/ciaf389
12
You’ve Got a Friend in Me: Curbside Questions Infectious Diseases Clinicians Ask Infectious Diseases Pharmacists
我是你的朋友：传染病临床医生向传染病药剂师咨询的即兴问题
Matthew R Davis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 58–61, https://doi.org/10.1093/cid/ciaf250
13
Home Testing for Contagious Illness: Historical Context and Modern Caveats
传染性疾病居家检测：历史背景与现代注意事项
Abigail Zuger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 62–66, https://doi.org/10.1093/cid/ciaf623
Fungal Infections（真菌感染）
14
Evaluating the Use of Lower Dose Flucytosine for the Treatment of Cryptococcal Meningitis: A Clinical Trial
评估低剂量氟胞嘧啶治疗隐球菌性脑膜炎的临床试验
Morris K Rutakingirwa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 67–74, https://doi.org/10.1093/cid/ciaf432
15
Association Between Duration of Candidemia and Clinical and Healthcare Resource Utilization Outcomes Among Hospitalized Adult Patients With Candidemia Who Received Empiric Treatment With an Echinocandin Across United States Hospitals
美国各医院中接受棘白菌素经验性治疗的念珠菌血症成年住院患者中，念珠菌血症持续时间与临床和医疗资源利用结局之间的关联
Thomas P Lodise and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 75–85, https://doi.org/10.1093/cid/ciaf472
16
Aspergillosis-Attributable Mortality in the United States: Analysis of Death Certificate Data
美国隐球菌病导致的死亡率分析：基于死亡证明数据
Thomas J Walsh and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 86–92, https://doi.org/10.1093/cid/ciaf653
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
17
Outcomes of Critical Illness in People With Advanced HIV Disease: 30 Years of Binational Data
晚期艾滋病患者危重症结局：30年的双国数据
Bryan Tan and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 93–99, https://doi.org/10.1093/cid/ciaf362
18
Phase 2 Trial of Long-Acting Cabotegravir and VRC07-523LS for Viral Suppression in Adults With HIV-1: ACTG A5357
长效卡博特韦和VRC07-523LS用于HIV-1感染成人病毒抑制的2期试验：ACTG A5357
Babafemi O Taiwo and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 100–108, https://doi.org/10.1093/cid/ciaf375
19
Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With HIV-1: First Results From the ANRS-MIE CARLAPOP Study
全国HIV-1感染者队列中长效卡博特韦和利匹韦林的治疗药物监测：ANRS-MIE CARLAPOP研究的首批结果
Nadège Néant and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 109–118, https://doi.org/10.1093/cid/ciaf385
20
Is Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine of Clinical Utility?
长效卡博特韦和利匹韦林的治疗药物监测是否具有临床实用性？
Catia Marzolini
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 119–121, https://doi.org/10.1093/cid/ciaf386
21
Efficacy and Safety of Dual Therapy With Dolutegravir/Lamivudine in Treatment-naive Persons With CD4 Counts <200/mm3: 48-Week Results of the DOLCE Study
多替拉韦/拉米夫定双药治疗在CD4计数<200/mm³的初治患者中的疗效和安全性：DOLCE研究48周结果
Maria Ines Figueroa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 122–131, https://doi.org/10.1093/cid/ciaf415
22
DOLCE: Sweet Success for Dolutegravir/Lamivudine?
DOLCE研究：多替拉韦/拉米夫定双药治疗是否取得完美成功？
Laura J Waters
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 132–133, https://doi.org/10.1093/cid/ciaf416
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
23
Real-Time Genomic Surveillance for Enhanced Healthcare Outbreak Detection and Control: Clinical and Economic Impact
实时基因组监测用于加强医疗保健机构疫情检测与控制：临床与经济影响
Alexander J Sundermann and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 134–141, https://doi.org/10.1093/cid/ciaf216
24
Patient Perspectives Regarding Different Contact Precaution Policies for Methicillin-resistant Staphylococcus aureus Across Two Hospitals: Patients Are in Favor of Contact Precautions
两家医院患者对耐甲氧西林金黄色葡萄球菌不同接触预防政策的态度：患者支持接触预防措施
Nicholas F Angelino and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 142–144, https://doi.org/10.1093/cid/ciaf330
Photo Quiz（影像问答）
25
The Clue That Wriggled into View
蜿蜒入目的线索
Nitin Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 145–147, https://doi.org/10.1093/cid/ciaf427
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
26
Comparing Generative Artificial Intelligence vs Experts for Detection of Catheter-Associated Urinary Tract Infection
比较生成式人工智能与专家在导管相关尿路感染检测中的应用
Shatha Alshanqeeti and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 148–150, https://doi.org/10.1093/cid/ciaf486
Sexually Transmitted Infections（性传播感染）
27
Viability of Chlamydia trachomatis in Different Anatomical Sites—a Systematic Review and Meta-analysis
不同解剖部位沙眼衣原体的存活能力——系统综述和荟萃分析
Arthur Wong and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 151–158, https://doi.org/10.1093/cid/ciae401
Photo Quiz（影像问答）
28
A 46-Year-Old With Persistent Altered Mental Status and Respiratory Failure
一例46岁患者持续出现意识状态改变伴呼吸衰竭
Ann F Yang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 159–161, https://doi.org/10.1093/cid/ciaf439
Sexually Transmitted Infections（性传播感染）
29
Mpox in People With HIV: Predictors of Diagnosis, Outcomes, and Vaccine Effectiveness in a Multisite Cohort
HIV感染者中的猴痘：多站点队列中诊断、预后和疫苗有效性的预测因素
Michalina Montaño and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 162–172, https://doi.org/10.1093/cid/ciae464
30
Development and Evaluation of a Novel Algorithm to Identify Doxycycline Postexposure Prophylaxis Users at a Large Healthcare System in the Bronx, New York
开发和评估一种新型算法，用于识别纽约布朗克斯区一家大型医疗系统中多西环素暴露后预防用药者
Caroline E Mullis and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 173–176, https://doi.org/10.1093/cid/ciaf109
31
Evidence-Informed Provision of Doxycycline Postexposure Prophylaxis for Prevention of Bacterial Sexually Transmitted Infections
为预防细菌性性传播感染提供基于证据的多西环素暴露后预防用药
Julia C Dombrowski and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages 177–184, https://doi.org/10.1093/cid/ciae527
Bacterial Infections（细菌性感染）
32
Long-term Mortality Trends Among Individuals With Tuberculosis: A Retrospective Cohort Study of Individuals Diagnosed With Tuberculosis in Brazil
巴西结核病患者的长期死亡率趋势：一项针对巴西结核病诊断患者的回顾性队列研究
Sun Kim and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e1–e8, https://doi.org/10.1093/cid/ciaf206
33
Clinical and Microbiological Characteristics of Meningococcal Eye Infections: Retrospective National Surveillance in England, 2010–2022
脑膜炎球菌眼部感染的临床和微生物学特征：2010 - 2022年英格兰全国回顾性监测
Stephen A Clark and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e9–e16, https://doi.org/10.1093/cid/ciaf274
34
Does Piperacillin-Tazobactam Increase Mortality Risk Compared With Cefepime? Collider Bias and the Importance of Assumptions in Instrumental Variable Analyses
与头孢吡肟相比，哌拉西林-他唑巴坦是否会增加死亡率风险？工具变量分析中的混杂偏倚和假设的重要性
Fergus Hamilton and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e17–e23, https://doi.org/10.1093/cid/ciaf317
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
35
Efficacy and Safety of Obeldesivir in High-Risk Nonhospitalized Patients With COVID-19 (BIRCH): A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study
奥贝德西韦在高危非住院COVID-19患者（BIRCH研究）中的疗效和安全性：一项3期、随机、双盲、安慰剂对照研究
Anca Streinu-Cercel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e24–e32, https://doi.org/10.1093/cid/ciaf406
36
Retreatment With Nirmatrelvir/Ritonavir Following Return of COVID-19 Symptoms and SARS-CoV-2 Positivity
COVID-19症状复发且SARS-CoV-2检测呈阳性后使用奈玛特韦/利托那韦重新治疗
Wuyan Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e33–e40, https://doi.org/10.1093/cid/ciaf548
Emerging Infections(新兴感染)
37
“I Didn’t Know Him Before the Pandemic… Now He's on My Speed Dial”: Strengthening Collaboration Between Infectious Diseases Physicians and State and Local Public Health for Future Public Health Emergencies
“疫情前我并不认识他……现在他已是我的快速拨号对象”：加强传染病医生与州和地方公共卫生部门在未来突发公共卫生事件中的合作
Diana Valencia and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e41–e46, https://doi.org/10.1093/cid/ciaf179
38
Identification of and Response to Influenza A(H5) in Off-the-Shelf Raw Milk—Santa Clara County, California, November–December 2024
2024年11 - 12月加利福尼亚州圣克拉拉县在现成生牛奶中检出甲型流感（H5）病毒及应对措施
Alessandra Løchen and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e47–e48, https://doi.org/10.1093/cid/ciaf420
39
The Indispensable Value of Small-Molecule Antivirals in Epidemic and Pandemic Preparedness
小分子抗病毒药物在流行病和大流行病防范中的不可或缺价值
Ruxandra Draghia-Akli and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e49–e55, https://doi.org/10.1093/cid/ciaf476
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
40
Increasing HIV Testing During Gonorrhea and Chlamydia Evaluations in Urgent Care and Emergency Departments: A Large Health System Initiative
在紧急护理和急诊科进行淋病和衣原体检测时增加HIV检测：一项大型医疗系统倡议
Allan M Seibert and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e56–e67, https://doi.org/10.1093/cid/ciaf434
41
Clinical Predictors and Incidence of Kaposi Sarcoma Among Males With HIV in the Treat-All Era in the United States and Canada
美国和加拿大“全员治疗”时代男性HIV感染者卡波西肉瘤的临床预测因素和发病率
Sally B Coburn and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e68–e77, https://doi.org/10.1093/cid/ciaf446
42
Integrase Strand Transfer Inhibitors for Treatment-experienced Young Adults With Perinatal HIV in the US: Immunologic, Virologic, and Anthropometric Outcomes
美国接受过治疗的围产期感染HIV的年轻成人使用整合酶链转移抑制剂的免疫学、病毒学和人体测量学结果
Kunjal Patel and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e78–e88, https://doi.org/10.1093/cid/ciaf538
43
Win Ratio Aligns With and Enhances Interpretation of REPRIEVE's Primary Findings
Win比值与REPRIEVE研究的主要发现一致并增强了其解释性
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e89–e92, https://doi.org/10.1093/cid/ciaf477
44
The Critical Importance of Clinical Use Case to Inform Point-of-Care Technology Development: A Case Study of HIV Nucleic Acid Assays in the United States
临床应用案例对于指导即时检测技术开发的重要性：以美国HIV核酸检测为例
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e93–e99, https://doi.org/10.1093/cid/ciaf510
Mycobacterial Infections（分枝杆菌感染）
45
Body Mass Index and Incident Tuberculosis in Close Tuberculosis Contacts
结核密切接触者中体重指数与新发结核病的关系
María B Arriaga and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e100–e109, https://doi.org/10.1093/cid/ciaf475
46
The Role of Youths in Within-Household Tuberculosis Transmission: A Household Contact Cohort Study
青年在家庭内结核病传播中的作用：一项家庭接触队列研究
Meredith B Brooks and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e110–e118, https://doi.org/10.1093/cid/ciaf490
47
Cost-effectiveness of Targeted Next-Generation Sequencing for Tuberculosis Drug-resistance Testing as an Alternative to the Standard of Care in South Africa
南非以靶向下一代测序作为结核病耐药检测标准护理方案的替代方案的成本效益分析
Alexandra de Nooy and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e119–e125, https://doi.org/10.1093/cid/ciaf495
48
Xpert MTB/RIF Cycle Threshold as a Marker of Tuberculosis (TB) Disease Severity: Implications for TB Treatment Stratification
Xpert MTB/RIF循环阈值作为结核病（TB）疾病严重程度的标志物：对结核病治疗分层的启示
Daniel J Grint and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e126–e134, https://doi.org/10.1093/cid/ciaf527
49
The Role of β-Lactam Antibiotics in Treating Mycobacterium abscessus: From Laboratory Insights to Clinical Applications and the Case for Clinical Trials
β-内酰胺类抗生素在治疗脓肿分枝杆菌中的作用：从实验室见解到临床应用及开展临床试验的必要性
Khalid M Dousa and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e135–e145, https://doi.org/10.1093/cid/ciaf547
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
50
Efficacy, Immunogenicity, and Safety of an Investigational Maternal Respiratory Syncytial Virus Prefusion F Protein–Based Vaccine
一种研究性孕产妇呼吸道合胞病毒融合前F蛋白疫苗的疗效、免疫原性和安全性
Peyman Banooni and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e146–e155, https://doi.org/10.1093/cid/ciaf033
51
Hepatotoxicity Among People With HIV and Receiving Isoniazid Preventive Therapy in Pregnancy and Postpartum: The Role of Antiretroviral Regimen and Pharmacogenetics
HIV感染者在孕期和产后接受异烟肼预防性治疗时的肝毒性：抗逆转录病毒治疗方案和药物基因组学的作用
Grace Montepiedra and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e156–e164, https://doi.org/10.1093/cid/ciaf198
52
Transplacental Transfer of Lumefantrine, Mefloquine, and Piperaquine: A Comparison of Concentrations in Mothers, Neonates, and Cord Blood
青蒿素、甲氟喹和哌喹的胎盘转运：母亲、新生儿和脐带血中浓度的比较
Makoto Saito and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e165–e173, https://doi.org/10.1093/cid/ciaf552
53
Why Did the Antimalarial Drug Cross the Placenta?
抗疟药为何要穿过胎盘？
Stephen J Rogerson and Holger W Unger
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e174–e175, https://doi.org/10.1093/cid/ciaf553
Viral Infections（病毒性传染病）
54
Kinetics and Predictors of Hepatitis B Surface Antigen Loss After Commencing Hepatitis B Virus (HBV)–Active Antiretroviral Therapy in the Setting of HIV and Chronic HBV Coinfection
HIV和慢性乙型肝炎病毒（HBV）共感染患者开始使用HBV活性抗逆转录病毒治疗后乙型肝炎表面抗原消失的动力学和预测因素
Jennifer Audsley and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e176–e184, https://doi.org/10.1093/cid/ciaf281
55
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病
Lauren A Powers and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e185–e190, https://doi.org/10.1093/cid/ciaf285
Correspondence（读者来信）
56
Unveiling Latent Risk Patterns in Antimicrobial-Resistant Bacteremia: A Deeper Look at Pathogen-Specific Mortality
揭示抗菌药物耐药性菌血症中的潜在风险模式：深入探究病原体特异性死亡率
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e191, https://doi.org/10.1093/cid/ciaf493
57
Resistance to Antibiotics With High Empiric Treatment Relevance Explains Attributable Mortality Across 110 Pathogen-antibiotic Combinations
对经验性治疗具有高度相关性的抗生素耐药性可解释110种病原体 - 抗生素组合的归因死亡率
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e191–e192, https://doi.org/10.1093/cid/ciaf494
58
Culture Clash: Dual-Pathogen Endocarditis and the Metagenomic Next-Generation Sequencing Studies We Need
文化冲突：双病原体心内膜炎以及我们所需的宏基因组下一代测序研究
Carl Boodman and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e193–e195, https://doi.org/10.1093/cid/ciaf518
59
Metagenomic Next-Generation Sequencing and Cardiovascular Infections: Promise and Pitfalls of Polymicrobial Detection
宏基因组下一代测序与心血管感染：多微生物检测的前景与陷阱
Sarwat Khalil and M Rizwan Sohail
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e196, https://doi.org/10.1093/cid/ciaf519
60
It Is Time to Go Beyond the Association Between Colistin and Meropenem for Invasive Carbapenem-Resistant Acinetobacter baumannii Infections
是时候超越多粘菌素和美罗培南联合治疗侵袭性碳青霉烯耐药鲍曼不动杆菌感染了
Alberto Enrico Maraolo and Giancarlo Ceccarelli
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e197–e198, https://doi.org/10.1093/cid/ciaf533
61
Actually, It May be Time to Return to Colistin and Meropenem in Some Patients Infected With Carbapenem-resistant Acinetobacter baumannii (CRAB)
实际上，对于某些感染碳青霉烯耐药鲍曼不动杆菌（CRAB）的患者，或许是时候重新使用多粘菌素和美罗培南了
Jason M Pogue and Keith S Kaye
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e198–e199, https://doi.org/10.1093/cid/ciaf534
62
COVID-19 and Bacterial Pneumonia: Protective Effect or Diagnostic Bias?
COVID-19和细菌性肺炎：保护作用还是诊断偏差？
Duygu Aydın and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e200, https://doi.org/10.1093/cid/ciaf539
63
Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections: A Follow Up
患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病：后续研究
John C Hu and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e200–e201, https://doi.org/10.1093/cid/ciaf540
64
Long-Acting Cabotegravir/Rilpivirine in Viremic People With HIV: Bumpy Road to Perfection
长效卡博特韦/利匹韦林用于病毒载量阳性的HIV感染者：通往完美的坎坷之路
Beatrice Barda and Marco Bongiovanni
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e201–e202, https://doi.org/10.1093/cid/ciaf482
65
Beyond the Sequence: Operationalizing Whole-Genome Sequencing for Real-time Infection Control in Low- and Middle-Income-Country Healthcare Settings Healthcare Settings
超越序列：在中低收入国家医疗环境中实际应用全基因组测序进行实时感染控制
Schawanya Kaewpitoon Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e202–e203, https://doi.org/10.1093/cid/ciaf535
66
Reassessing Adherence Trajectories in Multidrug-Resistant Tuberculosis: Recovery Advantage and Hidden Biases
重新评估耐多药结核病的依从性轨迹：康复优势和隐藏偏差
Shiuan-Chih Chen and Chun-Chieh Chen
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e203–e204, https://doi.org/10.1093/cid/ciaf536
67
Metagenomic Sequencing of Blood Culture Broth for Diagnosing Fastidious Endocarditis
血培养肉汤宏基因组测序用于诊断苛养性心内膜炎
Po-Hsiu Huang and others
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Pages e204–e205, https://doi.org/10.1093/cid/ciaf554
Corrections（更正）
68
Correction to: Secondary Pneumococcal Disease in Veterans With Viral Respiratory Infections
《患有病毒性呼吸道感染退伍军人的继发性肺炎球菌病》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e206, https://doi.org/10.1093/cid/ciaf572
69
Correction to: Treatment Outcomes With an Oral Short Course Regimen for Rifampicin-resistant Tuberculosis in a High HIV Prevalence, Programmatic Setting in South Africa
《南非高HIV流行率、项目化环境中口服短程利福平耐药结核病治疗方案的治疗结果》更正
Clinical Infectious Diseases, Volume 82, Issue 1, 15 January 2026, Page e207, https://doi.org/10.1093/cid/ciaf711
Clinical Infectious Diseases Volume 82 Issue Supplement_1
临床传染病学 82卷 增刊1期
https://academic.oup.com/cid/issue/82/Supplement_1
SUPPLEMENT（增刊）
Laboratory and Point-of-care Testing to Detect Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Available Evidence
实验室及即时检测技术用于检测沙眼衣原体和淋病奈瑟菌：现有证据综述
SUPPLEMENT ARTICLES（增刊论著）
1
Evidence Review for Centers for Disease Control and Prevention Guidance Development on the Detection of Chlamydia trachomatis and Neisseria gonorrhoeae
美国疾病控制与预防中心沙眼衣原体和淋病奈瑟菌检测指南制定证据综述
Amanda C Smith and Ellen N Kersh
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S1–S5, https://doi.org/10.1093/cid/ciaf665
2
Narrative Review of Chlamydia trachomatis Culture, Viability Testing, and Sequencing Methods
沙眼衣原体培养、活性检测及测序方法的叙述性综述
Alana K Sterkel and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S6–S12, https://doi.org/10.1093/cid/ciaf697
3
Culture and Identification of Neisseria gonorrhoeae: A Narrative Review of Current Laboratory Methods
淋病奈瑟菌培养与鉴定：当前实验室方法叙述性综述
Olusegun O Soge and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S13–S18, https://doi.org/10.1093/cid/ciaf698
4
Review of the Performance of Laboratory-Based Molecular Diagnostics for Chlamydia trachomatis and Neisseria gonorrhoeae
实验室分子诊断技术检测沙眼衣原体和淋病奈瑟菌的性能综述
Megan Crumpler and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S19–S35, https://doi.org/10.1093/cid/ciaf696
5
Review of Methods for Detecting Antimicrobial Resistance of Neisseria gonorrhoeae
淋病奈瑟菌抗菌药物耐药性检测方法综述
Kara K Mitchell and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S36–S42, https://doi.org/10.1093/cid/ciaf706
6
Point-of-care Tests for Chlamydia trachomatis and Neisseria gonorrhoeae: Review of the Literature
沙眼衣原体和淋病奈瑟菌即时检测技术文献综述
Yukari C Manabe and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_1, 15 February 2026, Pages S43–S51, https://doi.org/10.1093/cid/ciaf699
Clinical Infectious Diseases Volume 82 Issue 2
临床传染病学 82卷 2期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Interior of the Old Jersey Prison Ship in the Revolutionary War
美国革命战争中老泽西监狱船的内部景象
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page i, https://doi.org/10.1093/cid/ciaf693
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag011
IDSA 2025 Collections Editorial（美国传染病学会2025年专题合集社论）
3
2025 Content Collections from the IDSA Journals
IDSA期刊2025年内容合集
Roger Bedimo and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 185–186, https://doi.org/10.1093/cid/ciag041
State-of-the-Art Review（前沿综述）
4
State-of-the-Art Review: Chagas Disease—an Enduring Challenge
前沿综述：恰加斯病——一个持续存在的挑战
Nelson Iván Agudelo Higuita and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 187–205, https://doi.org/10.1093/cid/ciaf654
IDSA Features（美国传染病学会特色内容）
5
Policy Recommendations to Support Equitable Access to Long-Acting Injectables for HIV Prevention and Treatment: A Policy Paper of the Infectious Diseases Society of America and the HIV Medicine Association
支持公平获取用于艾滋病毒预防和治疗的长效注射剂的政策建议：美国传染病学会与艾滋病毒医学协会的政策文件
Julia L Marcus and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 206–211, https://doi.org/10.1093/cid/ciae648
Voices of ID（传染病之声）
6
A “Terminal Infection”
“绝症感染”
Jennifer Furin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 212–214, https://doi.org/10.1093/cid/ciaf332
Invited Commentary（特邀评论）
7
A Rapid Test to Differentiate Viral From Bacterial Infections: Searching for the Holy Grail
区分病毒与细菌感染的快速检测：寻找“圣杯”
Lao-Tzu Allan-Blitz and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 215–218, https://doi.org/10.1093/cid/ciaf585
Bacterial Infections（细菌感染）
8
Nonoperative Versus Neurosurgical Treatment of Brain Abscess: An Emulated Trial Nested Within a Nationwide, Population-Based Cohort
脑脓肿的非手术治疗与神经外科治疗：一项基于全国人群队列的模拟试验
Emilie Marie Eriksen and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 219–227, https://doi.org/10.1093/cid/ciaf304
9
What Is the Impact of Anti-Enterococcal Empirical Therapy on Survival of Patients With Enterococcal Bloodstream Infections?
抗肠球菌经验性治疗对肠球菌血流感染患者生存率的影响是什么？
Linda Bussini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 228–237, https://doi.org/10.1093/cid/ciaf323
10
Adjunctive Fosfomycin for the Treatment of Staphylococcus aureus Bacteremia: A Pooled Post Hoc Analysis of Individual Participant Data From 2 Randomized Trials
辅助使用磷霉素治疗金黄色葡萄球菌菌血症：两项随机试验个体参与者数据的汇总事后分析
Francesc Escrihuela-Vidal and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 238–245, https://doi.org/10.1093/cid/ciaf387
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
11
Kinetics of Non-nucleoside Reverse Transcriptase Inhibitor Resistance-associated Mutations in HIV-1 Proviral Cellular Reservoirs in Non-nucleoside Reverse Transcriptase Inhibitor-experienced Persons
在接受过非核苷类逆转录酶抑制剂治疗的HIV-1感染者中，非核苷类逆转录酶抑制剂耐药相关突变在HIV-1前病毒细胞储存库中的动力学
Thomas Drumel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 246–251, https://doi.org/10.1093/cid/ciaf430
12
Impact of Different Integrase Strand Transfer Inhibitors on Body Mass Index Among People With HIV Who Newly Started Antiretroviral Therapy in Shenzhen, China: A Real-World Data Analysis
中国深圳新开始抗逆转录病毒治疗的HIV感染者使用不同整合酶链转移抑制剂对体重指数的影响：一项现实数据分析
Lukun Zhang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 252–261, https://doi.org/10.1093/cid/ciaf466
13
Consequences of Stopping Antiretroviral Treatment in a Persistently Seronegative Individual with HIV-1
HIV-1持续血清阴性个体停止抗逆转录病毒治疗的后果
Marc Wirden and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 262–264, https://doi.org/10.1093/cid/ciaf422
14
Approaches to the Management of Virologic Failure on Dolutegravir-Based Antiretroviral Therapy in the 50 Countries With the Highest Adult HIV Prevalence
在成人HIV患病率最高的50个国家中，多替拉韦为基础的抗逆转录病毒治疗出现病毒学失败的治疗方法
Cameron T Nutt and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 265–273, https://doi.org/10.1093/cid/ciaf444
Mycobacterial Infections（结核分枝杆菌感染）
15
Retrospective Cohort Analysis for Identification of Discordant Rifampicin-resistant Xpert MTB/RIF Assay Results in South Kivu, Eastern Democratic Republic of the Congo, a High Burden Tuberculosis Setting
刚果民主共和国东部南基伍这一结核病高负荷地区，识别利福平耐药不一致的Xpert MTB/RIF检测结果的回顾性队列分析
Bertin C Bisimwa and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 274–281, https://doi.org/10.1093/cid/ciaf451
16
Prevention of Tuberculosis in Patients Treated With Biological Therapies: 20 Years' Experience in a Specialized Tuberculosis Clinic in a Low-prevalence Country
生物疗法治疗患者中结核病的预防：某低流行国家一个专科结核病诊所20年的经验
Sandra Pérez-Recio and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 282–290, https://doi.org/10.1093/cid/ciaf491
17
Reducing Household Tuberculosis Transmission: A Pilot Cluster-Randomized Controlled Trial
减少家庭内结核病传播：一项试点整群随机对照试验
Cinthya Ruiz-Tagle and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 291–298, https://doi.org/10.1093/cid/ciaf526
18
(Un)masking Tuberculosis
（揭开）结核病的“面具”
Joseph N Burzynski and Neil W Schluger
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 299–300, https://doi.org/10.1093/cid/ciaf528
19
Estimating the Accuracy and Additionality of TB-LAM to Diagnose TB in Children Without HIV (AccuLAM)
评估TB-LAM在无HIV儿童中诊断结核病的准确性和额外价值（AccuLAM）
Lucía CarratalàCastro and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 301–303, https://doi.org/10.1093/cid/ciaf525
Sexually Transmitted Infections（性传播感染）
20
Potential Impact of Doxycycline Post-exposure Prophylaxis Prescribing Strategies on Incidence of Bacterial Sexually Transmitted Infections
多西环素暴露后预防用药策略对细菌性性传播感染发病率的影响
Michael W Traeger and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 304–311, https://doi.org/10.1093/cid/ciad488
21
Filling in the Gaps: Updates on Doxycycline Prophylaxis for Bacterial Sexually Transmitted Infections
填补空白：多西环素预防细菌性性传播感染的最新进展
Aniruddha Hazra and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 312–320, https://doi.org/10.1093/cid/ciae062
22
Reported Neurologic Manifestations Among Persons With Syphilis by Stage of Infection—12 States, 2019–2022
2019-2022年12个州按感染阶段划分的梅毒患者报告的神经系统表现
Sarah B Wondmeneh and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 321–325, https://doi.org/10.1093/cid/ciaf015
Viral Infections（病毒性感染）
23
Investigating the Role of Cytomegalovirus as a Cause of Stillbirths and Child Deaths in Low- and Middle-Income Countries Through Postmortem Minimally Invasive Tissue Sampling
通过死后微创组织采样，调查巨细胞病毒在低收入和中等收入国家死胎和儿童死亡原因中的作用
Sithembiso Velaphi and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 326–336, https://doi.org/10.1093/cid/ciaf098
Photo Quiz（影像问答）
24
Bursting at the Seams
“撑破”
Maxwell Olenski and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 337–340, https://doi.org/10.1093/cid/ciaf488
Viral Infections（病毒性感染）
25
Clinical and Epidemiological Investigation of Vaccine-Derived Poliovirus Type 2 Outbreak in Pakistan During 2019–2021
2019-2021年巴基斯坦2型疫苗衍生脊髓灰质炎病毒疫情的临床和流行病学调查
Nayab Mehmood and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 341–351, https://doi.org/10.1093/cid/ciaf151
26
Inactivated Polio Vaccine Must Be an Essential Part of Polio Eradication
灭活脊髓灰质炎疫苗必须是根除脊髓灰质炎的重要组成部分
Konstantin Chumakov and Stanley A Plotkin
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 352–353, https://doi.org/10.1093/cid/ciaf215
Photo Quiz（影像问答）
27
Intracranial Lesion in a Patient With Chronic Myeloid Leukemia
慢性髓性白血病患者颅内病变
Mohammed Shakeel Sillat and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 354–357, https://doi.org/10.1093/cid/ciaf441
Viral Infections（病毒性感染）
28
Respiratory Syncytial Virus Co-Detection With Other Respiratory Viruses Is Not Significantly Associated With Worse Clinical Outcomes Among Children Aged <2 Years: New Vaccine Surveillance Network, 2016–2020
在<2岁的婴幼儿中，呼吸道合胞病毒与其他呼吸道病毒共同检测与临床预后恶化无显著关联：2016-2020年新疫苗监测网络数据
Justin Z Amarin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 358–365, https://doi.org/10.1093/cid/ciaf194
29
Transfer of Herpes Simplex Virus Type 1 (HSV-1) Specific T Cells in a Pediatric Patient Post-HSCT With Severe, Acyclovir-resistant HSV-1 Infection
一例异基因造血干细胞移植后严重、阿昔洛韦耐药的单纯疱疹病毒1型（HSV-1）感染患儿的HSV-1特异性T细胞的输注
Astrid Wintering and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages 366–369, https://doi.org/10.1093/cid/ciaf125
Clinical Trials（临床实验）
30
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
干扰素-α鼻喷雾剂预防可降低癌症患者新冠病毒感染率：一项随机、双盲、安慰剂对照试验
Michelle K Yong and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e208–e216, https://doi.org/10.1093/cid/ciaf409
31
A Phase 3, Randomized Trial Investigating the Safety, Tolerability, and Immunogenicity of V116, an Adult-Specific Pneumococcal Conjugate Vaccine, in Pneumococcal Vaccine-Naïve Adults 18–64 Years of Age at Increased Risk of Pneumococcal Disease, STRIDE-8
一项3期随机试验，调查V116（一种成人特异性肺炎球菌结合疫苗）在未接种过肺炎球菌疫苗且患肺炎球菌疾病风险增加的18-64岁年龄段成人中的安全性、耐受性和免疫原性，STRIDE-8试验
Paul T Scott and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e217–e226, https://doi.org/10.1093/cid/ciaf604
32
Effect of Direct-from-blood Bacterial Testing on Antibiotics Administration in Adults Presenting With Acute Infection: A Randomized Trial
直接从血液进行细菌检测对急性感染成年患者抗生素给药的影响：一项随机试验
David C Gaston and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e227–e235, https://doi.org/10.1093/cid/ciaf677
33
The Tantalizing Pursuit for a Perfect Diagnostic Test: Balancing Innovation With Stewardship
对完美诊断检测的诱人追求：平衡创新与管理
K C Coffey and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e236–e238, https://doi.org/10.1093/cid/ciaf674
Global Health and Neglected Tropical Diseases（全球健康与被忽视的热带病）
34
Diagnostic Accuracy of Tuberculosis Screening Tests in a Prospective Multinational Cohort: Chest Radiography With Computer-Aided Detection, Xpert Tuberculosis Host Response, and C-Reactive Protein
在一项前瞻性多国队列研究中，结核病筛查试验的诊断准确性：计算机辅助检测的胸部X光片、Xpert结核宿主反应检测和C反应蛋白
Rebecca Crowder and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e239–e247, https://doi.org/10.1093/cid/ciae549
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
35
Risk Assessment in a Global CVD Prevention Cohort of People With HIV by PCE, PREVENT, and SCORE2
通过PCE、PREVENT和SCORE2对全球心血管疾病预防队列中艾滋病毒感染者进行风险评估
Steven K Grinspoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e248–e257, https://doi.org/10.1093/cid/ciaf542
36
REPRIEVE Analysis of New Cardiovascular Risk Calculators in HIV: Underpredicting Risk Means Preventing Fewer Heart Attacks
HIV新心血管风险计算器的REPRIEVE分析：低估风险意味着预防的心脏病发作更少
Matthew S Durstenfeld
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e258–e261, https://doi.org/10.1093/cid/ciaf543
37
Comparable Inflammatory and Metabolic Outcomes After Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Continuing Dolutegravir/Lamivudine in Virologically Suppressed Adults With HIV (INSTINCT/GESIDA10918 Study)
在病毒学抑制的HIV感染成人中，转换为比克替拉韦/恩曲他滨/丙酚替诺福韦与继续使用多替拉韦/拉米夫定后的炎症和代谢结局相当（INSTINCT/GESIDA10918研究）
Sergio Serrano-Villar and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e262–e274, https://doi.org/10.1093/cid/ciaf565
38
Tenofovir Alafenamide and Body Weight: Have We Finally Tipped the Scale?
丙酚替诺福韦与体重：我们最终是否打破了平衡？
John R Koethe
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e275–e277, https://doi.org/10.1093/cid/ciaf566
39
Long-Term Clinical, Immunologic, and Viral Reservoir Outcomes in Children Treated With VRC01LS and 10-1074 Monoclonal Antibodies in the Tatelo Study
在Tatelo研究中，接受VRC01LS和10-1074单克隆抗体治疗的儿童的长期临床、免疫学和病毒储存库结局
Gbolahan Ajibola and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e278–e285, https://doi.org/10.1093/cid/ciaf568
40
Trends in Persons Prescribed HIV Postexposure Prophylaxis in the United States, 2015–2023
2015-2023年美国开具HIV暴露后预防处方的患者趋势
John N Le and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e286–e295, https://doi.org/10.1093/cid/ciaf581
Immunocompromised Hosts（免疫功能低下宿主）
41
Epidemiology, Risk Factors, and Outcomes of Neutropenic Enterocolitis in Onco-Hematological Patients According to Chemotherapy Regimen
根据化疗方案分析肿瘤血液学患者中性粒细胞减少性肠结肠炎的流行病学、危险因素和预后
Anne-Sophie Brunel and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e296–e307, https://doi.org/10.1093/cid/ciaf134
42
An Analysis of Cytomegalovirus-Specific Cell-Mediated Immunity in a Phase 3, Randomized, Placebo-Controlled Trial of Letermovir Prophylaxis in Cytomegalovirus-Seropositive Recipients of an Allogeneic Hematopoietic Cell Transplant
在一项3期随机、安慰剂对照试验中，分析来特莫韦预防对巨细胞病毒血清阳性异基因造血细胞移植受者巨细胞病毒特异性细胞介导免疫的影响
Genovefa A Papanicolaou and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e308–e315, https://doi.org/10.1093/cid/ciaf646
43
Cytomegalovirus (CMV)-Specific Cell-Mediated Immunity for Prediction of Postprophylaxis CMV Disease in a Phase 3 Trial of Letermovir Versus Valganciclovir Prophylaxis in Donor CMV-Seropositive/Recipient CMV-Seronegative Kidney Transplant Recipients
在供体巨细胞病毒血清阳性/受体巨细胞病毒血清阴性的肾移植受者中，来特莫韦与缬更昔洛韦预防的3期试验中，巨细胞病毒（CMV）特异性细胞介导免疫对预防后CMV疾病的预测作用
Ajit P Limaye and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e316–e324, https://doi.org/10.1093/cid/ciaf632
44
The Role of Cytomegalovirus-Specific Cellular Immunity in Transplant Recipients with Letermovir Prophylaxis: To be Determined
来特莫韦预防移植受者中巨细胞病毒特异性细胞免疫的作用：有待确定
Yoichiro Natori and Martina Sester
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e325–e327, https://doi.org/10.1093/cid/ciaf633
45
IL12RB1 Deficiency Appearing in North America: Expanding the Clinical Phenotypes
北美出现的IL12RB1缺陷：拓展临床表型
Chen Wang and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e328–e331, https://doi.org/10.1093/cid/ciaf637
Vaccines（疫苗）
46
A Phase IV, Open-label, Single-Arm, Multicentric Clinical Trial for Evaluation of Human Papillomavirus 9vHPV Vaccine Immunogenicity in Men Who Have Sex With Men With HIV: GeSIDA Study 10 017
一项评估人乳头瘤病毒9vHPV疫苗在感染HIV的男男性行为者中免疫原性的IV期、开放标签、单臂、多中心临床试验：GeSIDA 10 017研究
Raquel Ron and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e332–e342, https://doi.org/10.1093/cid/ciaf435
47
Immunogenicity and Safety of the COVID-19 Messenger RNA Vaccine Coadministered With Influenza and 23-valent Pneumococcal Polysaccharide Vaccines
与流感疫苗和23价肺炎球菌多糖疫苗同时接种的COVID-19信使核糖核酸疫苗的免疫原性和安全性
Omid Rezahosseini and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e343–e351, https://doi.org/10.1093/cid/ciaf455
48
Intestinal Mucosal Immune Responses to Novel Oral Poliovirus Vaccine Type 2 in Healthy Newborns
健康新生儿对新型2型口服脊髓灰质炎疫苗的肠道黏膜免疫反应
Audrey Godin and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e352–e360, https://doi.org/10.1093/cid/ciaf484
49
Estimated Vaccine Effectiveness for Respiratory Syncytial Virus–Related Acute Respiratory Illness in Older Adults: Findings From the First Postlicensure Season
老年人呼吸道合胞病毒相关急性呼吸道疾病的估计疫苗有效性：首个上市后季节的研究结果
Sara Y Tartof and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e361–e370, https://doi.org/10.1093/cid/ciaf496
Sexually Transmitted Infections（性传播感染）
50
Systematic Review and Meta-analysis of the Association Between Mycoplasma genitalium and Pelvic Inflammatory Disease (PID)
生殖支原体与盆腔炎性疾病（PID）关联的系统综述和荟萃分析
Kay Htaik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e371–e379, https://doi.org/10.1093/cid/ciae295
51
Sexually Transmitted Infection (STI)/HIV Testing, STIs, and HIV Pre-exposure Prophylaxis Use Among Men Who Have Sex With Men and Men Who Have Sex With Men and Women in the United States, 2019–2022
2019-2022年美国男男性行为者以及男男性行为者和女性性行为者中性传播感染（STI）/HIV检测、性传播感染和HIV暴露前预防用药情况
Guoyu Tao and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e380–e386, https://doi.org/10.1093/cid/ciae314
52
Cabotegravir Maintains Protective Efficacy in the Setting of Bacterial Sexually Transmitted Infections: A Secondary Analysis of HPTN 083
卡博特韦在细菌性性传播感染情况下维持保护效力：HPTN 083的二次分析
Meredith E Clement and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e387–e395, https://doi.org/10.1093/cid/ciae572
Viral Infections（病毒性感染）
53
Comprehensive Analysis of Cardiovascular Events and Risk Factors in Patients Hospitalized With Respiratory Syncytial Virus
对因呼吸道合胞病毒感染住院患者的心血管事件和危险因素的综合分析
Paulina Sudnik and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e396–e403, https://doi.org/10.1093/cid/ciaf310
54
In Critical Condition: The Urgent Need to Support Mpox Therapeutic and Diagnostic Pipelines
处于危急状况：迫切需要支持猴痘治疗和诊断管线
Carmen Perez Casas and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e404–e408, https://doi.org/10.1093/cid/ciaf529
Correspondence（读者来信）
55
Caution in Interpreting INSTIs and Weight in Observational Studies
在观察性研究中解读整合酶抑制剂与体重关系时需谨慎
Esteban Martínez
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Page e409, https://doi.org/10.1093/cid/ciaf569
56
Weight Trajectories With Integrase Inhibitors: Unaddressed Insights and Limitations in a Chinese Cohort
整合酶抑制剂与体重变化轨迹：中国队列中未解决的见解和局限性
Yuan-Ti Lee and Shiuan-Chih Chen
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e409–e410, https://doi.org/10.1093/cid/ciaf570
57
Real-World Evidence as a Complement to Randomized Trials in Interpreting Weight Gain on Modern INSTI Regimens
现实证据作为随机试验的补充，用于解读现代整合酶抑制剂方案导致的体重增加
Xinsheng Wu and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e410–e411, https://doi.org/10.1093/cid/ciaf571
58
C-reactive Protein in TB Meningitis: Signal, Surrogate, or Saboteur?
结核性脑膜炎中的C反应蛋白：信号、替代指标还是破坏因素？
Patrick K Moonan and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e411–e412, https://doi.org/10.1093/cid/ciaf575
59
C-Reactive Protein in Tuberculous Meningitis: A Viable Biomarker for Individualized Care
结核性脑膜炎中的C反应蛋白：个体化护理的可行生物标志物
Lillian Tugume and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e412–e413, https://doi.org/10.1093/cid/ciaf576
60
The Win Ratio Should Be Complemented by Other Win Statistics to Provide a Comprehensive Picture of Relative and Absolute Treatment Effects: The Case Study of the REPRIEVE Trial
胜利比率应与其他胜利统计数据相结合，以全面呈现相对和绝对治疗效果：REPRIEVE试验案例研究
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e413–e414, https://doi.org/10.1093/cid/ciaf587
61
Small Effects, Big Impact: Multiple Win Measures Aid Interpretation, But Do Not Forget the Bigger Picture
效应虽小，影响重大：多种胜利衡量指标有助于解读，但不要忘记整体情况
Emma Davies Smith and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e414–e416, https://doi.org/10.1093/cid/ciaf588
62
Does Oral Antibiotic Switching Therapy Show Similar Efficacy to Intravenous Administration for Treating Infective Endocarditis?
口服抗生素转换疗法治疗感染性心内膜炎的疗效是否与静脉给药相似？
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e416–e417, https://doi.org/10.1093/cid/ciaf598
63
Toward a Wider Use of Oral Antibiotic Switch in Infective Endocarditis
朝着更广泛地使用感染性心内膜炎口服抗生素转换疗法迈进
Romane Pouy and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e417–e418, https://doi.org/10.1093/cid/ciaf599
64
Operationalizing Sepsis Definitions With Artificial Intelligence: Toward Smarter Antibiotic Use
利用人工智能实现败血症定义的落地应用：迈向更明智的抗生素使用
James S Ford and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e418–e419, https://doi.org/10.1093/cid/ciaf601
65
Balancing Innovation in Artificial Intelligence With Practical Sepsis Definitions
平衡人工智能创新与实用的败血症定义
Chanu Rhee and Michael Klompas
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e419–e420, https://doi.org/10.1093/cid/ciaf602
66
Precision Prevention of Tuberculosis in Biologic Therapy: Lessons Beyond Screening Strategies
生物疗法中结核病的精准预防：筛查策略之外的启示
Shiuan-Chih Chen and Yuan-Ti Lee
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e420–e421, https://doi.org/10.1093/cid/ciaf559
67
Recalibrating COVID-19 Booster Policy: Lessons From Hybrid Immunity and Global Equity Gaps
重新调整COVID-19加强针政策：从混合免疫和全球公平差距中吸取教训
Nathkapach K Rattanapitoon and others
Clinical Infectious Diseases, Volume 82, Issue 2, 15 February 2026, Pages e421–e422, https://doi.org/10.1093/cid/ciaf605
Clinical Infectious Diseases Volume 82 Issue 3
临床传染病学 82卷 3期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Dracunculiasis, 1674
1674年的麦地那龙线虫病
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page i, https://doi.org/10.1093/cid/ciag089
In the Literature（文献聚焦）
2
In the Literature
文献聚焦
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag012
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Managing Vulvovaginal Candidiasis
前沿综述：外阴阴道念珠菌病的治疗
Riina Rautemaa-Richardson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 371–382, https://doi.org/10.1093/cid/ciaf673
Ethics Rounds（伦理探讨）
4
CARB Your Enthusiasm: An Ethics-Informed Analysis for Clinicians of the US National Action Plan for Combating Antibiotic-Resistant Bacteria
谨慎对待抗生素：基于伦理学分析美国国家抗耐药菌行动计划对临床医生的启示
Hunter Jackson Smith and Chelsea Modlin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 383–388, https://doi.org/10.1093/cid/ciaf478
Voices of ID（传染病之声）
5
Mothers
母亲们
Maria Koshy
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 389–390, https://doi.org/10.1093/cid/ciaf338
Bacterial Infections（细菌性感染）
6
The Impact of Synergistic Therapy Between Colistin and Meropenem on Outcomes of People With Pneumonia or Bloodstream Infection Due to Carbapenem-Resistant Gram-Negative Pathogens
多粘菌素与美罗培南联合治疗对碳青霉烯类耐药革兰氏阴性菌所致肺炎或血行感染患者预后的影响
Mariya Huralska and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 391–398, https://doi.org/10.1093/cid/ciaf398
7
We Cannot Overcome the Mediocrity of Colistin
我们无法忽视多粘菌素的平庸疗效
Jason C Gallagher
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 399–401, https://doi.org/10.1093/cid/ciaf592
8
Comparing Clinical, Microbiological, and Genetic Definitions of Relapse in Patients With Subsequent Episodes of Methicillin-resistant Staphylococcus aureus Bone and Joint Infection
比较耐甲氧西林金黄色葡萄球菌骨关节感染后续发作患者复发在临床、微生物学和遗传学上的定义
Kevin Bouiller and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 402–410, https://doi.org/10.1093/cid/ciaf448
9
Non-Klebsiella pneumoniae Carbapenemase Attributes of the Newer β-lactam/β-lactamase Inhibitors, Part 2: Burkholderia cepacia Complex, Stenotrophomonas maltophilia, and Acinetobacter baumannii
新型β-内酰胺/β-内酰胺酶抑制剂对非肺炎克雷伯菌碳青霉烯酶的抗菌特性，第二部分：洋葱伯克霍尔德菌复合群、嗜麦芽窄食单胞菌和鲍曼不动杆菌
Andrew J Fratoni and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 411–419, https://doi.org/10.1093/cid/ciaf403
Clinical Trials（临床试验）
10
Continuation Versus Temporary Interruption of Immunomodulatory Agents During Infections in Patients With Inflammatory Rheumatic Diseases: A Randomized Controlled Trial
炎症性风湿性疾病患者感染期间继续使用与暂时停用免疫调节剂的随机对照试验
Merel A A Opdam and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 420–426, https://doi.org/10.1093/cid/ciaf442
11
Effectiveness of Nebulized Bronchodilator-Enhanced Sputum Induction in Thai Patients With Presumed Pulmonary Tuberculosis: A Randomized Controlled Trial (NeB-TB Trial)
泰国疑似肺结核患者中雾化支气管扩张剂增强痰诱导的有效性：一项随机对照试验（NeB-TB试验）
Pichanon Mingchay and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 427–435, https://doi.org/10.1093/cid/ciaf580
12
Bone Biopsy not Superior to Ulcer Bed Biopsy–guided Antibacterial Therapy on Remission of Diabetic Foot Osteomyelitis: A Randomized Controlled Trial
在指导用于缓解糖尿病足骨髓炎的抗菌治疗方面骨活检并不优于溃疡床活检：一项随机对照试验
Rimke S Lagrand and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 436–442, https://doi.org/10.1093/cid/ciaf684
13
Do We Need a Bone Biopsy for Managing Diabetic Foot Osteomyelitis?
我们是否需要对糖尿病足骨髓炎进行骨活检？
Eric M Senneville and Benjamin A Lipsky
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 443–445, https://doi.org/10.1093/cid/ciaf685
Critical Care and Sepsis（重症监护与败血症）
14
Contamination of Blood Cultures Drawn From Arterial Catheters Versus Venipuncture or Venous Catheters in Critically Ill Patients: A Systematic Review and Meta-analysis
危重患者从动脉导管与静脉穿刺或静脉导管采集血培养的污染情况：一项系统综述和荟萃分析
Takatoshi Koroki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 446–452, https://doi.org/10.1093/cid/ciaf260
15
Reassessing Procalcitonin-Guided Antibiotic Therapy in Critically Ill Patients With Sepsis: Lessons From the ADAPT-Sepsis Trial
重新评估降钙素原指导的败血症危重患者抗生素治疗：来自ADAPT-败血症试验的启示
Simran Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 453–458, https://doi.org/10.1093/cid/ciaf336
Infection Control and Hospital Epidemiology（传染病控制与医院流行病学）
16
Effectiveness and Safety of Methods to Prevent Bloodstream and Other Infections and Noninfectious Complications Associated With Peripherally Inserted Central Catheters: A Systematic Review and Meta-Analysis
预防经外周静脉置入中心静脉导管相关血行感染及其他感染和非感染性并发症的方法的有效性和安全性：一项系统综述和荟萃分析
Andreea Dobrescu and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 459–472, https://doi.org/10.1093/cid/ciaf063
17
Using Generative Artificial Intelligence for Healthcare-Associated Infection Surveillance
利用生成式人工智能进行医院感染监测
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 473–479, https://doi.org/10.1093/cid/ciaf619
18
Artificial Intelligence and the Future of Healthcare-Associated Infection Surveillance: Bridging Precision, Partnership, Practice, and People
人工智能与医院感染监测的未来：融合精准、合作、实践与人文
Mamdooh Alzyood
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 480–483, https://doi.org/10.1093/cid/ciaf620
Infections in Older Adults（老年传染病学）
19
Evaluation of Influenza Antiviral Prophylaxis for Long-term Care Residents: A Systematic Review and Meta-Analysis
长期护理机构居民流感抗病毒预防的效果评价：一项系统综述和荟萃分析
Ryan Hanula and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 484–493, https://doi.org/10.1093/cid/ciaf101
20
Implementation of Diagnostic Stewardship to Improve Urinary Tract Infection Antibiotic Use Across 3 Medical Centers
在三家医疗中心实施诊断管理以改善尿路感染抗生素的使用
Kimberly C Claeys and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 494–500, https://doi.org/10.1093/cid/ciaf411
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
21
Adverse Events of First-Line Therapy for Pediatric Tuberculosis: A Systematic Review and Meta-Analysis
儿童结核病一线治疗的不良反应：一项系统综述和荟萃分析
Michael Prodanuk and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 501–512, https://doi.org/10.1093/cid/ciaf152
22
The Impact of Pregnancy on Tuberculosis Treatment Outcomes: An Analysis of Brazilian National Surveillance Data 2016–2022
妊娠对结核病治疗效果的影响：基于2016-2022年巴西国家监测数据的分析
Silvia S Chiang and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 513–521, https://doi.org/10.1093/cid/ciaf233
Photo Quiz（影像问答）
23
Persistent Fever and Back Pain After Liver Transplantation
肝移植后持续发热和背痛
Toshiyuki Kishida and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 522–525, https://doi.org/10.1093/cid/ciaf489
Pediatric and Maternal Infectious Diseases（儿科与孕产妇传染病）
24
Stool Processing Methods for Xpert Ultra Testing in Childhood Tuberculosis: A Prospective, Multicountry Accuracy Study
儿童结核病Xpert Ultra检测的粪便处理方法：一项前瞻性、多国准确性研究
Devan Jaganath and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 526–534, https://doi.org/10.1093/cid/ciaf289
Photo Quiz（影像问答）
25
A Bloom Beneath the Skin
皮下绽放之花
Yi Rong Chew and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 535–538, https://doi.org/10.1093/cid/ciaf550
Vector-Borne Diseases（虫媒传染病）
26
Trends in Anaplasmosis Over the Past Decade: A Review of Clinical Features, Laboratory Data, and Outcomes
过去十年无形体病趋势：临床特征、实验室数据和预后回顾
Silpita Katragadda and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 539–547, https://doi.org/10.1093/cid/ciaf171
27
Completion of Paired Serological Testing Algorithms for Spotted Fever Rickettsiosis and Ehrlichiosis, North Carolina: 2017–2020
斑点热立克次体病和埃里希体病配对血清学检测算法的完成情况，北卡罗来纳州：2017-2020年
Huipeng Liao and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages 548–555, https://doi.org/10.1093/cid/ciaf176
COVID-19/SARS-COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Effect of Metformin on the Risk of Post-COVID-19 Condition Among Individuals With Overweight or Obese: A Population-based Retrospective Cohort Study
二甲双胍对超重或肥胖人群患新冠后综合征风险的影响：一项基于人群的回顾性队列研究
Ubonphan Chaichana and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e423–e432, https://doi.org/10.1093/cid/ciaf429
29
Preventing Long COVID With Metformin
使用二甲双胍预防新冠长期症状
Carolyn T Bramante and David R Boulware
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e433–e435, https://doi.org/10.1093/cid/ciaf700
30
Effectiveness of COVID-19 Vaccination and Prior Infections to Reduce Long COVID Risk During the Pre-Omicron and Omicron Periods
COVID-19疫苗接种和既往感染在奥密克戎变异株出现前及奥密克戎时期降低新冠长期症状风险的有效性
Sara Carazo and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e436–e445, https://doi.org/10.1093/cid/ciaf549
31
International Collaboration to Develop and Harmonize Drug Interaction Guidance for Nirmatrelvir/Ritonavir During COVID-19: Lessons Learned for Future Pandemic Preparedness
国际合作制定并统一新冠期间奈玛特韦/利托那韦药物相互作用指南：为未来大流行准备汲取的经验教训
Safia Kuriakose and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e446–e454, https://doi.org/10.1093/cid/ciaf606
Endovascular Infections（血管内感染）
32
Antifungal Therapy in Candida Infective Endocarditis: A Comparison of Echinocandins and Other Treatment Regimens in a Nationwide Cohort Study
念珠菌感染性心内膜炎的抗真菌治疗：一项全国队列研究中棘白菌素与其他治疗方案比较
Siri Kurland and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e455–e461, https://doi.org/10.1093/cid/ciaf312
33
Should We Extend the Use of Oral Antibiotics in Infective Endocarditis? The ENDO-ORAL Study
我们是否应延长感染性心内膜炎口服抗生素的使用？ENDO-ORAL研究
Benoit Rallet and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e462–e470, https://doi.org/10.1093/cid/ciaf452
34
Rethinking the Routine: Are Repeat Blood Cultures Necessary After Completion of Infective Endocarditis Treatment?
重新思考常规做法：感染性心内膜炎治疗完成后是否需要重复血培养？
Jean Regina and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e471–e474, https://doi.org/10.1093/cid/ciaf617
35
Posttreatment Blood Cultures in Patients With Infective Endocarditis: Valuable, Inconsequential, or Worse?
感染性心内膜炎患者治疗后的血培养：有价值、无关紧要还是有害？
Daniel C DeSimone and Larry M Baddour
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e475–e476, https://doi.org/10.1093/cid/ciaf618
Fungal Infections（真菌感染）
36
Fungal Meningitis in US Patients Who Received Epidural Anesthesia in Matamoros, Mexico
在墨西哥马塔莫罗斯接受硬膜外麻醉的美国患者中的真菌性脑膜炎
Dallas J Smith and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e477–e484, https://doi.org/10.1093/cid/ciaf399
37
Empirical Antifungal Treatment of Critically ⅢPatients With Influenza-Associated Acute Respiratory Distress Syndrome: A Propensity Score Weighted Observational Study
流感相关急性呼吸窘迫综合征危重患者的经验性抗真菌治疗：一项倾向评分加权观察性研究
Stefan Hatzl and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e485–e493, https://doi.org/10.1093/cid/ciaf507
38
Is Empirical Antifungal Therapy the Next Path Forward in Patients With Influenza-Associated ARDS?
经验性抗真菌治疗是否是流感相关急性呼吸窘迫综合征患者的下一步治疗方向？
Florian Reizine and Jean-Pierre Gangneux
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e494–e496, https://doi.org/10.1093/cid/ciaf508
39
Valley Fever in Central California: Diagnosis is Not the Finish Line, the Real Gap is Longitudinal Care
加利福尼亚州中部山谷热：诊断并非终点，真正的差距在于纵向护理
Geetha Sivasubramanian
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e497–e502, https://doi.org/10.1093/cid/ciaf728
Hepatitis（肝炎）
40
The Hepatitis C Cascade of Care for Opioid Agonist Therapy Recipients in Australia
澳大利亚接受阿片类激动剂治疗者的丙型肝炎治疗流程
Samara Griffin and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e503–e510, https://doi.org/10.1093/cid/ciaf352
41
Trends in Hepatitis C Virus Infection Prevalence Among People With HIV in Spain Over 2 Decades (2002–2023)
西班牙20多年来（2002-2023年）HIV感染者中丙型肝炎病毒感染流行率的趋势
Juan Berenguer and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e511–e520, https://doi.org/10.1093/cid/ciaf407
42
Gaps in the Hepatitis C Prenatal and Postpartum Care Cascade: Rationale for Treatment in Pregnancy
丙型肝炎围产期和产后治疗流程中的差距：孕期治疗的理由
Andrew B Mendlowitz and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e521–e533, https://doi.org/10.1093/cid/ciaf578
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
43
Combined Use of Ibalizumab and Lenacapavir for the Treatment of Multidrug-resistant HIV-1: A Case Series
艾巴利珠单抗和来那卡帕韦联合治疗多重耐药HIV-1：病例系列研究
Charlotte Rolle and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e534–e540, https://doi.org/10.1093/cid/ciaf597
44
New Strategies for a Vexing Problem: Injectables to the Rescue for People With Multidrug-Resistant HIV
棘手问题的新策略：注射剂助力多重耐药HIV感染者
William R Short and Onyema E Ogbuagu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e541–e543, https://doi.org/10.1093/cid/ciaf600
45
The Bounce-back Effect: What Happens After Cessation of Low-dose Semaglutide in People With HIV
反弹效应：HIV感染者停用低剂量司美格鲁肽后会发生什么
Kristine M Erlandson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e544–e548, https://doi.org/10.1093/cid/ciaf652
46
Infections After Kidney Transplantation From Donors With HIV to Recipients With HIV
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况
Elizabeth C Arant and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e549–e557, https://doi.org/10.1093/cid/ciaf656
47
Infections After Kidney Transplantation from Donors with HIV to Recipients with HIV: Insights, Prevention, and the Path Forward
HIV阳性供体肾脏移植给HIV阳性受者后的感染情况：见解、预防和未来方向
Abhay Dhand and Stephanie M Pouch
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e558–e560, https://doi.org/10.1093/cid/ciaf657
Respiratory Infections（呼吸道传染病）
48
Multimorbidity Profiles and Severe In-Hospital Outcomes in Adults With Respiratory Syncytial Virus
成人呼吸道合胞病毒感染的多病共存情况及严重院内结局
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e561–e570, https://doi.org/10.1093/cid/ciaf405
49
Characterizing Treatment Adherence Trajectories in the endTB Multisite Cohort of Drug-Resistant Tuberculosis Patients: An Application of Group-Based Trajectory Modeling
在endTB多站点耐药结核病患者队列中描述治疗依从性轨迹：基于组别的轨迹建模应用
Stephanie Law and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e571–e579, https://doi.org/10.1093/cid/ciaf467
50
Severity of Clinical Presentation and Outcomes in Hospitalized Adult People With Influenza by Type and Subtype, United States—2017–2020
2017 - 2020年美国按流感类型和亚型划分的住院成人流感患者临床表现严重程度及预后
Seana Cleary and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e580–e588, https://doi.org/10.1093/cid/ciaf545
51
Reported Tuberculosis Symptoms: An Inadequate Classifier of Disease State
报告的结核病症状：疾病状态分类的不足指标
Nicky McCreesh and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e589–e594, https://doi.org/10.1093/cid/ciaf611
Sexually Transmitted Infections（性传播感染）
52
Effectiveness of Updated 2023–2024 (Monovalent XBB.1.5) COVID-19 Vaccination Against SARS-CoV-2 Omicron XBB and BA.2.86/JN.1 Lineage Hospitalization and a Comparison of Clinical Severity—IVY Network, 26 Hospitals, 18 October 2023–9 March 2024
2023 - 2024年更新版（单价XBB.1.5）新冠疫苗对SARS-CoV-2奥密克戎XBB和BA.2.86/JN.1谱系住院的有效性及临床严重程度比较——IVY网络，26家医院，2023年10月18日 - 2024年3月9日
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e595–e603, https://doi.org/10.1093/cid/ciae405
53
High Prevalence of Haemophilus ducreyi Among Patients With Suspected Primary syphilis in Malawi, 2019–2022
2019 - 2022年马拉维疑似原发性梅毒患者中杜克雷嗜血杆菌的高流行率
Mitch M Matoga and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e604–e611, https://doi.org/10.1093/cid/ciaf114
54
Characteristics Associated With Disseminated Gonococcal Infections vs Uncomplicated Gonorrhea: A California Case-control Study, 2021–2022
与播散性淋球菌感染（而非单纯性淋病）相关的特征：2021 - 2022年加利福尼亚病例对照研究
Kelly A Johnson and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e612–e615, https://doi.org/10.1093/cid/ciaf311
Viral Infections（病毒性感染）
55
Anal Human Papillomavirus Infection Progression to Disease Among Men Who Have Sex With Men
男男性行为者肛门人乳头瘤病毒感染进展为疾病的情况
Joel M Palefsky and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e616–e625, https://doi.org/10.1093/cid/ciaf584
Correspondence（读者来信）
56
Cardiac Complications of Mycoplasma pneumoniae: Overlooked Confounders, Biomarkers, and Host-Driven Shifts
肺炎支原体感染的心脏并发症：被忽视的混杂因素、生物标志物及宿主驱动的变化
Shiuan-Chih Chen and Ming-Cheng Lin
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e626–e627, https://doi.org/10.1093/cid/ciaf609
57
Mycoplasma pneumoniae–Associated Cardiac Complications Revisited
重新审视肺炎支原体相关心脏并发症
Daniel Grupel and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e627–e628, https://doi.org/10.1093/cid/ciaf610
58
Screening for Anal Cancer Is Associated With Real Harms and Questionable Benefits
肛门癌筛查存在实际危害且益处存疑
Chris Kenyon
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e628, https://doi.org/10.1093/cid/ciaf613
59
Anal Cancer Screening: A Balanced Approach is Necessary
肛门癌筛查：需采取平衡的方法
Hayden S Andrews and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e628–e629, https://doi.org/10.1093/cid/ciaf614
60
Collateral Benefits and Methodological Limits of Respiratory Syncytial Virus Immunization for Infant Otitis Media and Antibiotic Use
呼吸道合胞病毒免疫接种对婴儿中耳炎和抗生素使用的附带益处及方法学局限
Tsai Ling Ting and Kai-Lun Sheu
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e629–e630, https://doi.org/10.1093/cid/ciaf640
61
Interpretation of Respiratory Syncytial Virus Immunization Impact on Pediatric Acute Otitis Media: Key Considerations
解读呼吸道合胞病毒免疫接种对儿童急性中耳炎的影响：关键考量因素
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e630–e631, https://doi.org/10.1093/cid/ciaf641
62
A Possible Increase in Penicillin-Resistant Strains of Treponema pallidum
梅毒螺旋体青霉素耐药菌株可能增加
Jun Suzuki and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e631–e632, https://doi.org/10.1093/cid/ciaf643
63
Surveillance of Resistance-Associated Mutations in Treponema pallidum
梅毒螺旋体耐药相关突变的监测
Kai-Hsiang Chen and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e632–e633, https://doi.org/10.1093/cid/ciaf645
64
Does Empirical Antifungal Therapy Reduce IAPA in Influenza-Associated ARDS? Methodological Concerns on Diagnosis, Surveillance, and Clinical Heterogeneity
经验性抗真菌治疗能否减少流感相关急性呼吸窘迫综合征（IAPA）的发生？诊断、监测和临床异质性方面的方法学问题
Ming Xue and others
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Pages e633–e634, https://doi.org/10.1093/cid/ciaf661
65
Empirical Antifungal Therapy and IAPA in Influenza-Associated ARDS: Insights from Real-World Data
流感相关急性呼吸窘迫综合征中的经验性抗真菌治疗和IAPA：来自现实数据的见解
Stefan Hatzl and Robert Krause
Clinical Infectious Diseases, Volume 82, Issue 3, 15 March 2026, Page e634, https://doi.org/10.1093/cid/ciaf664
Clinical Infectious Diseases Volume 82 Issue Supplement_2
临床传染病学 82卷 增刊2期
https://academic.oup.com/cid/issue/82/Supplement_2
SUPPLEMENT（增刊）
Advancing Tuberculosis Research Through RePORT International: Enhancing Treatment Outcomes, Predicting Disease Progression, and Improving Diagnosis
通过结核病区域性前瞻性观察研究国际联盟（RePORT International）推动结核病研究：提高治疗效果、预测疾病进展及改善诊断
SUPPLEMENT ARTICLES（增补论著）
1
A Narrative Review of the Regional Prospective Observational Research in Tuberculosis International Consortium: Sharing Diverse Data and Specimens in the Fight Against Tuberculosis
结核病区域性前瞻性观察研究国际联盟的叙述性综述：在抗击结核病中共享多样数据和样本
Rajita Bhavaraju and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S53–S59, https://doi.org/10.1093/cid/ciag151
2
Long-term Sequelae of Pulmonary Tuberculosis: A Narrative Review
长期肺部结核后遗症：一项叙述性综述
Akshay N Gupte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S60–S67, https://doi.org/10.1093/cid/ciag123
3
From Exposure to Disease: Predicting Tuberculosis Progression
从接触感染到发病：预测结核病进展
Mariana Araújo-Pereira and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S68–S74, https://doi.org/10.1093/cid/ciag125
4
Asymptomatic Tuberculosis Across the Disease Spectrum: A Scoping Review of Epidemiology, Diagnosis, and Public Health Implications
疾病谱中的无症状结核：一项关于流行病学、诊断和公共卫生影响的范围综述
Beatriz Barreto Duarte and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_2, 15 April 2026, Pages S75–S84, https://doi.org/10.1093/cid/ciag150
Clinical Infectious Diseases Volume 82 Issue 4
临床传染病学 82卷 4期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时光的传染病学技艺）
1
La Petite Vérole
天花
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page i, https://doi.org/10.1093/cid/ciag118
In the Literature（文献精选）
2
In the Literature
文献精选
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag013
Joint Editorial（联合社论）
3
Protocols for Randomized Controlled Trials: Advancing Transparency in Infectious Diseases
随机对照试验方案：推动传染病领域透明度提升
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page 557, https://doi.org/10.1093/cid/ciag198
Clinical Dilemmas in Infectious Diseases（临床传染病疑难杂症）
4
Uncertain Terrain
不确定的领域
Kap Sum Foong and Sara W Dong
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 558–561, https://doi.org/10.1093/cid/ciaf283
Voices of ID（传染病之声）
5
Lessons I Learned from Our Soldier
我从我们的士兵身上学到的经验
Mitchell J Schwaber
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 562–563, https://doi.org/10.1093/cid/ciaf433
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
6
Long-Acting Cabotegravir/Rilpivirine, Lenacapavir, and Ibalizumab Use Among Persons With HIV-1 Viremia at a Ryan White-Funded Clinic in the Urban US South
美国南部城市由瑞安·怀特资助的诊所中，HIV-1病毒血症患者使用长效卡博特韦/利匹韦林、来那卡帕韦和艾巴利珠单抗的情况
Jonathan A Colasanti and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 564–574, https://doi.org/10.1093/cid/ciaf425
7
In the Mismatch: Viral Suppression Despite Low Tenofovir-Diphosphate in Dried Blood Spots in the Multicenter AIDS Cohort Study/Women's Interagency HIV Study Combined Cohort
矛盾现象：在多中心艾滋病队列研究/妇女跨机构HIV研究联合队列中，尽管干燥血斑中磷酸替诺福韦水平低，但仍能实现病毒抑制
Sarah C Mann and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 575–582, https://doi.org/10.1093/cid/ciaf509
8
Prognostic Value of Blood Epigenetic Biomarkers of Aging in Persons With Well-Controlled HIV-1 Infection
血液衰老表观遗传生物标志物在HIV-1感染控制良好人群中的预后价值
Patricia Martínez-Martín and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 583–591, https://doi.org/10.1093/cid/ciaf537
9
HIV Resistance to Dolutegravir Varies With Coadministered Agents
HIV对多替拉韦的耐药性随联合用药的不同而有所差异
Ingrid A Beck and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 592–596, https://doi.org/10.1093/cid/ciaf481
Immunocompromised Hosts（免疫功能低下宿主）
10
Letermovir Prophylaxis Guided by Cytomegalovirus Cell-Mediated Immunity Improves the Outcomes of Allogeneic Hematopoietic Stem Cell Transplant Recipients
基于巨细胞病毒细胞介导免疫的莱特莫韦预防可改善异体基因造血干细胞移植受者的预后
Luxiang Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 597–606, https://doi.org/10.1093/cid/ciaf410
11
Changing Clinical and Laboratory Characteristics of Progressive Multifocal Leukoencephalopathy: A Retrospective National Cohort Study
进行性多灶性白质脑病临床和实验室特征的变化：一项回顾性全国队列研究
Ilaria Mainardi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 607–617, https://doi.org/10.1093/cid/ciaf501
12
Respiratory Syncytial Virus After Chimeric Antigen Receptor T-cell Therapy: Risk Factors and Outcomes in a Multicenter Retrospective Cohort
嵌合抗原受体T细胞疗法后呼吸道合胞病毒感染：一项多中心回顾性队列研究中的风险因素和预后
Maria Isabel Sotelo-Alva and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 618–621, https://doi.org/10.1093/cid/ciag052
Respiratory Infections（呼吸道感染）
13
Infectious Diseases Society of America (IDSA) Position Statement: Why IDSA Did Not Endorse the Community-Acquired Pneumonia Guidelines 2025 Update
美国传染病学会（IDSA）立场声明：为何IDSA未认可《2025年社区获得性肺炎指南》更新版
Michael Klompas and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 622–624, https://doi.org/10.1093/cid/ciaf625
14
We Dissent: Lessons From the 2025 Community-Acquired Pneumonia Guidelines
我们持不同意见：从《2025年社区获得性肺炎指南》中汲取的教训
Leila S Hojat and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 625–629, https://doi.org/10.1093/cid/ciaf626
15
Associations Between Antibiotic Use and Outcomes in Patients Hospitalized With Community-Acquired Pneumonia and Positive Respiratory Viral Assays
社区获得性肺炎且呼吸道病毒检测呈阳性住院患者抗生素使用与预后的关联
Brett Biebelberg and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 630–638, https://doi.org/10.1093/cid/ciaf687
16
Comparative Effectiveness of Azithromycin Versus Doxycycline in Hospitalized Patients With Community-Acquired Pneumonia Treated With Beta-Lactams: A Multicenter Matched Cohort Study
联合β-内酰胺类药物治疗社区获得性肺炎的住院患者中，阿奇霉素与多西环素疗效的比较：一项多中心匹配队列研究
Yewande E Odeyemi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 639–647, https://doi.org/10.1093/cid/ciaf252
17
Target Trial Emulation of Empiric Antibiotics on Clinical Outcomes in Moderately Immunocompromised Patients Hospitalized With Pneumonia
针对中度免疫功能低下肺炎住院患者，经验性抗生素对临床预后的目标试验模拟研究
Louis Saravolatz and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 648–657, https://doi.org/10.1093/cid/ciaf344
18
Impact of Respiratory Syncytial Virus Immunization on the Rate of Pediatric Acute Otitis Media: A Time-series Analysis
呼吸道合胞病毒免疫接种对儿童急性中耳炎发生率的影响：一项时间序列分析
Inès Fafi and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 658–664, https://doi.org/10.1093/cid/ciaf564
Vaccines（疫苗）
19
LC16m8 for Pre-exposure Prophylaxis Against Mpox in a High-Risk Population: An Open-Label Randomized Trial
使用LC16m8针对高危人群进行猴痘暴露前预防：一项开放标签随机试验
Nobumasa Okumura and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 665–672, https://doi.org/10.1093/cid/ciaf074
20
Immunogenicity and Safety of 2 Versus 3 Doses of 9-Valent Vaccine Against Human Papillomavirus in Women With Human Immunodeficiency Virus: The Papillon Randomized Trial
在感染人类免疫缺陷病毒的女性中，接种2剂与3剂九价人乳头瘤病毒疫苗的免疫原性和安全性：Papillon随机试验
Deborah Konopnicki and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 673–681, https://doi.org/10.1093/cid/ciaf241
21
Screening and Vaccination Rates for Tetanus, Hepatitis A, and Hepatitis B Among Individuals With Substance Use Disorders Hospitalized in an Integrated US Health System
在美国综合医疗机构中住院的成瘾性患者的破伤风、甲型肝炎和乙型肝炎筛查及接种率
Jennifer H Ku and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 682–688, https://doi.org/10.1093/cid/ciaf251
22
Atrial Fibrillation After Respiratory Syncytial Virus Vaccination Among Older Adults
老年人接种呼吸道合胞病毒疫苗后发生心房颤动的情况
Morgan Birabaharan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 689–691, https://doi.org/10.1093/cid/ciae649
23
Approaches to Comparing Influenza Vaccine Effectiveness to Guide Potential Preferential Product Recommendations
比较流感疫苗有效性的方法，以指导可能的优先产品推荐
Edward A Belongia and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 692–697, https://doi.org/10.1093/cid/ciaf563
Viral Infections（病毒性感染）
24
Clinical Features and Outcomes of Human Herpesvirus-6 DNAemia in Critically Ill Patients: A Retrospective Multicenter Analysis
危重患者人类疱疹病毒6型DNA血症的临床特征和预后：一项回顾性多中心分析
Margot Combet and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 698–708, https://doi.org/10.1093/cid/ciaf199
25
Kaposi Sarcoma–Associated Herpesvirus Risk and Disease in Kidney Donors and Transplant Recipients With HIV in the United States
美国HIV感染肾捐赠者和移植受者中卡波西肉瘤相关疱疹病毒的风险和疾病
Puja H Nambiar and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 709–719, https://doi.org/10.1093/cid/ciaf229
26
Clinical Outcomes of Mpox Disease in Patients Treated With Tecovirimat
接受特考韦瑞治疗的猴痘病患者的临床预后
Ciarra Leocadio and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 720–726, https://doi.org/10.1093/cid/ciaf520
27
Effective Antivirals in Pandemic Preparedness: Past Mistakes, Future Needs
大流行防范中的有效抗病毒药物：过去的错误，未来的需求
Antonios-Periklis Panagiotopoulos and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 727–733, https://doi.org/10.1093/cid/ciaf648
Photo Quizzes（影像问答）
28
From Soil to Skin: An Unexpected Cause of Necrotizing Cellulitis
从土壤到皮肤：坏死性蜂窝织炎的意外病因
Erica Peak and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 734–737, https://doi.org/10.1093/cid/ciaf555
29
A 67-year-Old Immunocompromised Male Presenting With Right Upper-Quadrant Abdominal Pain and Hepatic Lesions
一例67岁免疫功能低下男性，出现右上腹疼痛和肝脏病变
Sara Yousef Zadeh Shoushtari and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages 738–741, https://doi.org/10.1093/cid/ciaf729
Bacterial Infections（细菌性感染）
30
Patient-reported Perceptions, Experiences, and Preferences Around Intravenous and Oral Antibiotics for the Treatment of Staphylococcus aureus Bacteremia: A Descriptive Qualitative Study
金黄色葡萄球菌菌血症患者对静脉和口服抗生素治疗的自我报告认知、体验和偏好：一项描述性质性研究
Genevieve Walls and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e635–e642, https://doi.org/10.1093/cid/ciaf522
31
Reproducible Identification of Staphylococcus aureus Bacteremia Clinical Subphenotypes
金黄色葡萄球菌菌血症临床亚型的可重复性识别
Maaike C Swets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e643–e651, https://doi.org/10.1093/cid/ciaf655
32
Disease Trends and Mortality From Invasive Pneumococcal Disease: A Long-Term Population-Based Study
侵袭性肺炎球菌病的疾病趋势和死亡率：一项长期人群基础研究
Hörður Tryggvi Bragason and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e652–e661, https://doi.org/10.1093/cid/ciaf670
33
When and How to Use Subcutaneous Antibiotics
皮下注射抗生素的使用时机和方法
Stefano Di Bella and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e662–e673, https://doi.org/10.1093/cid/ciaf691
Clinical Trials（临床实验）
34
Using the Comparing Oral versus Parenteral Antimicrobial Therapy (COPAT) Clinical Trial to Influence Institutional Practice Transformation Towards Earlier Transition to Oral Antibiotics
利用口服与肠外抗菌治疗比较（COPAT）临床实验推动机构实践转型，以更早地过渡到口服抗生素治疗
Joy J Juskowich and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e674–e681, https://doi.org/10.1093/cid/ciaf707
35
The Fate of Oral Meds
口服药物的命运
Monica V Mahoney
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e682–e683, https://doi.org/10.1093/cid/ciaf708
36
Early Symptom Response in Patients With Uncomplicated Urinary Tract Infection Treated With Gepotidacin or Nitrofurantoin: Pooled Analysis From Two Pivotal Phase 3 Studies
接受吉泊西汀或呋喃妥因治疗的无并发症尿路感染患者的早期症状反应：两项关键性3期研究的汇总分析
Amanda J Sheets and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e684–e692, https://doi.org/10.1093/cid/ciaf722
37
Regional Variations of Rates and Determinants of Drug Resistance Mutations in People Failing First-line Therapy for HIV-1: A Substudy from the D2EFT Phase 3b/4 Clinical Trial
HIV-1一线治疗失败人群中耐药突变发生率和决定因素的区域差异：D2EFT 3b/4期临床试验的子研究
Billal Musah Obeng and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e693–e704, https://doi.org/10.1093/cid/ciaf739
38
What's Hot This Year in ID Clinical Science 2025
2025年传染病临床学科领域的年度热点
Jeffrey A Freiberg and Patty W Wright
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e705–e709, https://doi.org/10.1093/cid/ciaf740
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
39
Impact of Vaginal Estradiol on the Genitourinary Syndrome of Menopause, Vaginal Microbiome and Mucosal Immune Mediators in Women With HIV
阴道雌二醇对HIV感染女性绝经生殖泌尿综合征、阴道微生物群和黏膜免疫介质的影响
Kerry Murphy and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e710–e719, https://doi.org/10.1093/cid/ciaf669
40
Pharmacokinetics of Twice-daily Tenofovir Alafenamide in Adults With HIV-associated Tuberculosis on Bictegravir/Emtricitabine/Tenofovir Alafenamide and Rifampicin
在接受比克替拉韦/恩曲他滨/丙酚替诺福韦和利福平治疗的HIV相关结核病成人患者中，每日两次丙酚替诺福韦的药代动力学
Emmanuella Chinonso Osuala and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e720–e727, https://doi.org/10.1093/cid/ciaf732
41
Integrating HIV and Stimulant-Use Disorder Treatment: A Pilot Implementation Effectiveness Trial of Contingency Management in HIV Care
整合HIV和兴奋剂使用障碍治疗：在HIV护理中开展应急管理试点实施效果试验
Ayesha Appa and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e728–e734, https://doi.org/10.1093/cid/ciag006
42
Hepatitis B Reactivation in a US Cohort of People With HIV and Hepatitis B Core Antibody After Switch to Antiretroviral Therapy Without Hepatitis B Activity
美国HIV和乙型肝炎核心抗体阳性人群在转换为无抗乙肝病毒活性的抗逆转录病毒治疗后乙型肝炎复发的队列研究
Rachel V Denyer and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e735–e742, https://doi.org/10.1093/cid/ciag001
43
Hepatitis B Virus Reactivation in People With HIV After Treatment With Non-hepatitis B Virus-Active Antiretroviral Therapy
接受无抗乙肝病毒活性的抗逆转录病毒治疗的HIV感染者乙型肝炎病毒复发情况
Amir M Mohareb and Anders Boyd
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e743–e745, https://doi.org/10.1093/cid/ciag002
44
The Potential Effect of Ending Centers for Disease Control and Prevention Funding for HIV Tests: A Modeling Study in 18 States
终止美国疾病控制与预防中心对HIV检测资助的潜在影响：对18个州的建模研究
Ruchita Balasubramanian and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e746–e754, https://doi.org/10.1093/cid/ciag038
45
Cutting Federal Funds for HIV Testing Means Not Ending the HIV Epidemic
削减HIV检测的联邦资金意味着无法终结HIV流行
Sarah E Scott and Joshua A Barocas
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e755–e756, https://doi.org/10.1093/cid/ciag039
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
46
Cluster-Randomized Controlled Trial of Enhanced Carbapenem-Resistant Enterobacterales Prevention Program in General Medicine Wards, Siriraj Hospital
西拉查医院普通内科病房强化碳青霉烯类耐药肠杆菌科细菌预防计划的整群随机对照试验
Apiradee Taweesuk and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e757–e764, https://doi.org/10.1093/cid/ciaf523
47
Risk Factors Associated With Progression to Clinical Candida auris Infection Among Adults With Previous Colonization—Florida, 2019–2023
2019-2023年佛罗里达州既往定植的成人进展为临床耳念珠菌感染的相关风险因素
Katharine E Saunders and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e765–e772, https://doi.org/10.1093/cid/ciaf551
48
Using Generative Artificial Intelligence to Identify Central Line–associated Bloodstream Infections
利用生成式人工智能识别中心静脉导管相关血流感染
Daniel J Morgan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e773–e780, https://doi.org/10.1093/cid/ciaf636
49
Infection Control in Carceral Facilities
监狱设施中的感染控制
Amadin A Olotu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e781–e790, https://doi.org/10.1093/cid/ciaf479
50
Infection Prevention and Control in Carceral Settings
监狱环境中的感染预防与控制
April N McDougal and Lara B Strick
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e791–e793, https://doi.org/10.1093/cid/ciaf480
51
Impact of Discontinuation of Contact Precautions on Healthcare-associated Extended Spectrum β-Lactamase-Producing Escherichia coli in a Large Tertiary Care Hospital: An Interrupted Time-series Analysis
一家大型三级医院停止接触预防措施对医院获得性产超广谱β-内酰胺酶大肠埃希菌的影响：一项中断时间序列分析
Stefano Musumeci and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e794–e798, https://doi.org/10.1093/cid/ciaf594
Respiratory Infections（呼吸道感染）
52
Estimating Risk of Guillain-Barré Syndrome in US Medicare-enrolled Older Adults Following Medically Attended Respiratory Syncytial Virus Disease: A Self-controlled Case Series Analysis
美国医疗保险参保老年人因需就医的呼吸道合胞病毒疾病后患吉兰-巴雷综合征的风险评估：一项自我对照病例系列分析
Caihua Liang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e799–e806, https://doi.org/10.1093/cid/ciaf621
53
Independent Testing to Accelerate the Development of Lateral Flow Assays for Influenza A, Influenza B and SARS-COV-2
独立检测以加速甲型流感、乙型流感和严重急性呼吸系统综合征冠状病毒2型侧流层析检测法的开发
Anuradha Rao and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e807–e815, https://doi.org/10.1093/cid/ciaf660
54
Diagnostic Yield of Tongue Swab- Compared to Sputum-Based Molecular Testing for Tuberculosis in Four High-Burden Countries
在四个高负担国家，与痰液分子检测相比，舌拭子检测对结核病的诊断效果
Caitlin A Moe and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e816–e823, https://doi.org/10.1093/cid/ciag077
55
Are We Ready for the Gift Tongues Can Give to Tuberculosis?
我们准备好接受舌头为结核病诊断带来的“馈赠”了吗？
Michael R Barer
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e824–e825, https://doi.org/10.1093/cid/ciag078
Sexually Transmitted Infections（性传播感染）
56
Evaluating the Impact of Implementing and Scaling-Up the Use of Syphilis Rapid/Point-of-Care Tests: An Interrupted Time Series Analysis of New Syphilis Positivity Rates in Alberta, Canada
评估实施和扩大梅毒快速/即时检测使用的影响：加拿大阿尔伯塔省新发梅毒阳性率的中断时间序列分析
L Alexa Thompson and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e826–e835, https://doi.org/10.1093/cid/ciaf651
57
Human Papillomavirus-Related Anal Precancerous Lesions in Men Who Have Sex With Men: A Comparative Study of Pre-exposure Prophylaxis Users and HIV-Positive Individuals
男男性行为者中与人乳头瘤病毒相关的肛门癌前病变：暴露前预防用药者与HIV阳性者的对比研究
Magali Surmont and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e836–e842, https://doi.org/10.1093/cid/ciaf724
58
Is 3 Really What We Need? Relative Effectiveness of Benzathine Penicillin G and Doxycycline Treatment Regimens for Late or Unknown Duration Syphilis in 6 US Jurisdictions, 2016–2021
我们需要“3”吗？2016-2021年美国6个司法管辖区晚期或病程不明梅毒患者使用苄星青霉素G和多西环素治疗方案的相对疗效
River A Pugsley and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e843–e851, https://doi.org/10.1093/cid/ciag099
59
Strong Real-World Evidence That a Single Dose of Benzathine Penicillin G or a 28-Day Course of Oral Doxycycline Is Not Inferior to 3 Doses of Benzathine Penicillin G for the Treatment of Late Latent or Unknown Duration Syphilis
强力现实证据表明，单剂苄星青霉素G或28天口服多西环素治疗晚期潜伏梅毒或病程不明梅毒的疗效并不逊于3剂苄星青霉素G
Noah Kojima and Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e852–e854, https://doi.org/10.1093/cid/ciag101
Vaccines（疫苗）
60
Safety, Tolerability, and Immunogenicity of Revaccination With mRNA-1345, an mRNA Vaccine Against Respiratory Syncytial Virus, Administered 12 Months Following a Primary Dose in Adults Aged ≥50 Years
对≥50岁成年人，在初次接种12个月后再次接种针对呼吸道合胞病毒的mRNA疫苗mRNA-1345的安全性、耐受性和免疫原性
Jaya Goswami and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e855–e862, https://doi.org/10.1093/cid/ciaf515
61
Analysis of Antibody Markers as Immune Correlates of Risk of Severe COVID-19 in the PREVENT-19 Efficacy Trial of the NVX-CoV2373 Recombinant Protein Vaccine
在NVX-CoV2373重组蛋白疫苗PREVENT-19有效性试验中，抗体标志物作为严重新型冠状病毒肺炎风险免疫相关因素的分析
Youyi Fong and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e863–e874, https://doi.org/10.1093/cid/ciaf558
62
Is It Time to Reassess the Target Age of Human Papillomavirus Vaccination Globally?
现在是时候重新评估全球人乳头瘤病毒疫苗接种的目标年龄了吗？
Edie Brassington and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e875–e883, https://doi.org/10.1093/cid/ciaf679
63
Preschool or Infant Human Papillomavirus Immunization?
学龄前还是婴儿期接种人乳头瘤病毒疫苗？
Mark A Kane and Eduardo L Franco
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e884–e886, https://doi.org/10.1093/cid/ciaf678
Correspondence（读者来信）
64
Caution in Interpreting Equivalence From Nonsignificant Findings in Antiretroviral Switch Studies
谨慎解读抗逆转录病毒药物转换研究中非显著性结果得出的等效性结论
Esteban Martinez
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e887–e888, https://doi.org/10.1093/cid/ciaf675
65
Clarifying INSTINCT: Switching From Dolutegravir/Lamivudine to Bictegravir/Emtricitabine/Tenofovir Shows Comparable Inflammatory and Weight Outcomes
阐明INSTINCT研究：从多替拉韦/拉米夫定转换为比克替拉韦/恩曲他滨/丙酚替诺福韦显示出相似的炎症和体重结果
Sergio Serrano-Villar and Santiago Moreno
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e888–e889, https://doi.org/10.1093/cid/ciaf676
66
Can Doxycycline Prophylaxis Indirectly Reduce Congenital Syphilis?
多西环素预防能否间接降低先天性梅毒的发生率？
Kalpana Gopalkrishnan and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e889–e891, https://doi.org/10.1093/cid/ciaf694
67
The Urgency of Now: Congenital Syphilis in the Doxycycline Post-exposure Prophylaxis Era
迫在眉睫：多西环素暴露后预防时代的先天性梅毒问题
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Page e891, https://doi.org/10.1093/cid/ciaf695
68
Routine HIV RNA Testing During Injectable Cabotegravir and Oral Preexposure Prophylaxis Use
注射用卡博特韦和口服暴露前预防用药期间进行常规HIV RNA检测
Angelo Roberto Raccagni and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e891–e892, https://doi.org/10.1093/cid/ciaf702
69
Simplifying Testing for Human Immunodeficiency Virus During Pre-exposure Prophylaxis Monitoring
简化暴露前预防监测期间的人类免疫缺陷病毒检测
Weiming Zhu and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e892–e893, https://doi.org/10.1093/cid/ciaf703
70
Methodological Considerations in Evaluating Oral Antivirals for B-Cell-Depleted Patients
评估B细胞耗竭患者口服抗病毒药物的方法学考量
Wenjing Chen and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e893–e894, https://doi.org/10.1093/cid/ciaf717
71
Target Trial Emulation of Oral Antivirals for B-Cell-Depleted COVID-19 Patients—Reply to Chen et al
B细胞耗竭型新型冠状病毒肺炎患者口服抗病毒药物的靶试验模拟——回复Chen等人的评论
Xiaofeng F Wang and others
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e894–e895, https://doi.org/10.1093/cid/ciaf718
72
Misleading Conclusion That Is Not in Accordance With the Results of the Reported Randomized, Controlled Trial
与所报告的随机对照试验结果不符的误导性结论
Charlotte Strøm
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e895–e896, https://doi.org/10.1093/cid/ciaf659
73
Vaccine Policy Pendulum: A Lesson From Japan
疫苗政策摇摆不定：日本的教训
Masaki Machida and Wakaba Fukushima
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e896–e897, https://doi.org/10.1093/cid/ciaf689
74
Herpes Zoster, Vaccine, and Stroke Risk
带状疱疹、疫苗与中风风险
Shih-Wei Lai and Sheng-Chun Chiu
Clinical Infectious Diseases, Volume 82, Issue 4, 15 April 2026, Pages e897–e898, https://doi.org/10.1093/cid/ciaf725
Clinical Infectious Diseases Volume 82 Issue Supplement_4
临床传染病学 82卷 增刊4期
https://academic.oup.com/cid/issue/82/Supplement_4
SUPPLEMENT（增刊）
IDWeek Industry Highlights 2025
传染病之周2025 行业亮点
SUPPLEMENT ARTICLES（增补论著）
1
Selected Industry Highlights From IDWeek 2025
传染病之周2025 精选行业亮点
Jean-Jacques Parienti and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S85–S86, https://doi.org/10.1093/cid/ciag206
2
Differing Presentations of Excess Visceral Abdominal Fat in People Living With HIV: Two Clinical Cases Highlighting Distinct Therapeutic Pathways With Tesamorelin and Glucagon-Like Peptide-1 Receptor Agonists
HIV感染者内脏腹部脂肪过多的不同表现：两例临床病例展示特沙莫瑞林与胰高血糖素样肽-1受体激动剂的不同治疗路径
Robin Beach and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S87–S91, https://doi.org/10.1093/cid/ciag121
3
Metagenomic Next-generation Sequencing in Central Nervous System Infections: Clinical Strategies, Evidence, and Best Practices
宏基因组二代测序在中枢神经系统感染中的应用：临床策略、证据与最佳实践
Greer Waldrop and Sumanth P Reddy
Clinical Infectious Diseases, Volume 82, Issue Supplement_4, 15 May 2026, Pages S92–S99, https://doi.org/10.1093/cid/ciag120
Clinical Infectious Diseases Volume 82 Issue 5
临床传染病学 82卷 5期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（穿越时代的传染病技艺）
1
Vaccination Detail, Detroit Industry
疫苗接种细节，底特律工业
Mary Grizzard and Michael Grizzard
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page i, https://doi.org/10.1093/cid/ciag119
In the Literature（本期精选）
2
In the Literature
本期精选
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages ii–iv, https://doi.org/10.1093/cid/ciag180
Voices of ID（传染病之声）
3
Infected With the Academic Bug
染上学术热
Sigrun Einarsdottir
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 743–744, https://doi.org/10.1093/cid/ciaf546
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
4
Predictive Value of C-reactive Protein for Hospitalization and Mortality Among People With Advanced HIV Disease in Uganda Receiving the World Health Organization-recommended Package of Care
C反应蛋白对乌干达接受世界卫生组织推荐治疗方案的晚期HIV疾病患者住院和死亡的预测价值
Elizabeth L Schwartz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 745–752, https://doi.org/10.1093/cid/ciaf560
5
Effects of Semaglutide on Cognitive Function in People With HIV: A Randomized, Controlled Trial
塞马谷肽对HIV感染者认知功能的影响：一项随机对照试验
Ornina Atieh and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 753–761, https://doi.org/10.1093/cid/ciaf577
6
Earlier Initiation of Treatment Following HIV Acquisition Reduces Non-AIDS-defining Malignancy Risk
HIV感染后尽早启动治疗可降低非艾滋病相关性恶性肿瘤风险
Iris A J van der Wulp and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 762–772, https://doi.org/10.1093/cid/ciaf595
7
Let's Get It Started: Early Antiretroviral Treatment After HIV Acquisition Reduces Non–AIDS-Defining Malignancies
让我们开始吧：HIV感染后尽早启动抗逆转录病毒治疗可减少非艾滋病相关性恶性肿瘤
Nancy Crum
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 773–775, https://doi.org/10.1093/cid/ciaf596
8
Trends in Age-Related Health Outcomes in People with HIV in Spain, 2006–2023
2006–2023年西班牙HIV感染者年龄相关健康结局的趋势
Javier Martínez-Sanz and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 776–784, https://doi.org/10.1093/cid/ciaf622
9
Emergent HIV-1 Drug Resistance in Randomized Trials of Contemporary Antiretroviral Regimens
当代抗逆转录病毒方案随机试验中新发HIV-1耐药性
Josep M Llibre and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 785–798, https://doi.org/10.1093/cid/ciaf471
Infection Control and Hospital Epidemiology（感染控制与医院流行病学）
10
Mycobacterium tuberculosis Transmission in Healthcare Settings: A Systematic Review of Frequency, Risk Factors, and Exposure Conditions
医疗机构中结核分枝杆菌传播：频率、危险因素及暴露条件的系统综述
Fizza Manzoor and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 799–807, https://doi.org/10.1093/cid/ciag053
Medical Microbiology（医学微生物学）
11
Metagenomic Next-generation Sequencing of Cerebrospinal Fluid: First-year Experience at a Tertiary Referral Hospital
脑脊液宏基因组二代测序：一家三级转诊医院首年经验
Sergio Alvarez Mulett and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 808–814, https://doi.org/10.1093/cid/ciaf390
12
Navigating Nomenclature in Patient Care: Taxonomy Considerations From the College of American Pathologists’Microbiology Committee
患者诊疗中的命名导航：美国病理学家学会微生物学委员会的分类学考量
Jennifer Dien Bard and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 815–821, https://doi.org/10.1093/cid/ciaf474
13
Implementing Point-of-Care Testing in Infectious Diseases
在感染性疾病中实施床旁检测
Jean-Claude Nguyen Van and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 822–828, https://doi.org/10.1093/cid/ciaf650
Mycobacterial Infections（分枝杆菌感染）
14
Impact of Diabetes Mellitus in Tuberculosis (TB) Patients on TB Transmission
糖尿病对结核病（TB）患者TB传播的影响
Chuan-Chin Huang and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 829–840, https://doi.org/10.1093/cid/ciaf647
15
Association of Mycobacterium avium paratuberculosis With Crohn's Disease: A Large Multicenter Study From a Tuberculosis-Endemic Region
副结核分枝杆菌与克罗恩病的关联：来自结核病流行地区的一项大型多中心研究
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 841–847, https://doi.org/10.1093/cid/ciaf738
16
Short-Course Tuberculosis Preventive Therapy in a High Migration Setting: Early Experience With 1HP in Cook County, Illinois
高移民背景下的短程结核病预防性治疗：库克县（伊利诺伊州）1HP方案的早期经验
Samuel Starke and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 848–851, https://doi.org/10.1093/cid/ciaf723
17
Role of Low-Dose Infliximab for Inflammatory Complications of Central Nervous System Tuberculosis: A Retrospective Cohort Study
低剂量英夫利昔单抗在中枢神经系统结核炎性并发症中的作用：一项回顾性队列研究
Selwyn Selva Kumar D and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 852–856, https://doi.org/10.1093/cid/ciaf573
18
Targeting Inflammation in Tuberculous Meningitis Treatment
靶向结核性脑膜炎治疗中的炎症
Guy E Thwaites
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 857–859, https://doi.org/10.1093/cid/ciaf574
Pediatric and Maternal Infectious（儿科与孕产妇感染）
19
A 15-year Single-center Analysis of Late-onset Group B Streptococcus Infection Correlating Clinical Severity With Pathogen Virulence Determinants
晚发型B族链球菌感染的15年单中心分析：临床严重程度与病原体毒力因子的相关性
Carl Britto and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 860–867, https://doi.org/10.1093/cid/ciaf603
20
Evaluating Personal and Environmental Decolonization Strategies for Children With Skin and Soft Tissue Infection and Their Households — A Randomized Clinical Trial
评估皮肤和软组织感染儿童及其家庭的个人与环境去定植策略——一项随机临床试验
Alaina L Robinson and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 868–877, https://doi.org/10.1093/cid/ciaf627
Surgical Infectious Diseases（外科感染）
21
Impact of Vancomycin-Resistant Enterococci (VRE)–Active Perioperative Prophylaxis in Liver Transplant Patients Colonized by VRE
万古霉素耐药肠球菌（VRE）主动围手术期预防对VRE定植肝移植受者的影响
Giulia Jole Burastero and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 878–887, https://doi.org/10.1093/cid/ciaf121
22
Cephalosporins Versus Non-cephalosporin Antibiotics for Perioperative Prophylaxis in Primary Arthroplasty: A Systematic Review and Meta-Analysis
头孢菌素与非头孢菌素类抗生素在初次关节置换术围手术期预防中的比较：系统综述与荟萃分析
Rita Igwilo-Alaneme and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 888–900, https://doi.org/10.1093/cid/ciag172
Photo Quizzes（影像问答）
23
Safari Souvenir: A Case of Fever in a Returning Traveler
safari纪念品：一例返程旅行者发热病例
Nicole L Kusnik and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 901–903, https://doi.org/10.1093/cid/ciag129
24
Diagnostic Pitfalls—When First Appearances Can Deceive
诊断陷阱——当表象具有欺骗性
Annie Caldwell and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages 904–907, https://doi.org/10.1093/cid/ciag044
Clinical Trials（临床试验）
25
Evaluation of a Remote Therapeutic Monitoring Device and Integrated Care Platform in Outpatient Parenteral Antimicrobial Therapy
远程治疗监测设备与综合护理平台在门诊肠外抗微生物治疗中的评估
Emily A Siegrist and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e899–e909, https://doi.org/10.1093/cid/ciag009
26
Dolutegravir Reduces Human T-Cell Lymphotropic Virus Type 1 Proviral Load and Improves Neurological Outcomes in a Phase 2 Controlled Trial
多替拉韦降低人T淋巴细胞病毒1型前病毒载量并改善神经系统预后：一项2期对照试验
Carlos Brites and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e910–e920, https://doi.org/10.1093/cid/ciag163
27
Dolutegravir Appears to Lower Human T-Cell Lymphotropic Virus Type 1 (HTLV-1) Proviral Load: The Emerging Rational Approach to Treatment of HTLV-1–Associated Myelopathy
多替拉韦似乎可降低人T淋巴细胞病毒1型（HTLV-1）前病毒载量：HTLV-1相关脊髓病治疗的新兴理性方法
Eric A Meyerowitz
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e921–e922, https://doi.org/10.1093/cid/ciag164
COVID-19 / SARS COV-2（新冠肺炎/严重急性呼吸综合征冠状病毒2型）
28
Overlapping Clinical Presentation of Long COVID and Postacute COVID-19 Vaccination Syndrome: Phenotypes, Severity, and Biomarkers
长效新冠与急性新冠疫苗接种后综合征的临床表现重叠：表型、严重程度及生物标志物
Lawrence Purpura and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e923–e931, https://doi.org/10.1093/cid/ciaf624
29
Integrating Genomic Data into Test-negative Designs for Estimating Lineage-specific COVID-19 Vaccine Effectiveness
将基因组数据整合入检测阴性设计以估计谱系特异性COVID-19疫苗有效性
Kevin C Ma and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e932–e941, https://doi.org/10.1093/cid/ciag059
Hepatitis（肝炎）
30
Risk of Hepatocellular Carcinoma After Direct-Acting Antiviral Treatment for Hepatitis C Virus Infection in People With HIV
HIV感染者经直接抗病毒药物治疗丙型肝炎病毒后肝细胞癌的风险
Daniela K van Santen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e942–e950, https://doi.org/10.1093/cid/ciaf635
31
Fatal Overdose, Acute Viral Hepatitis, and HIV Attributed to Injection Drug Use, Appalachian Region of the United States, 2000–2023
阿巴拉契亚地区2000–2023年注射吸毒导致的致命过量、急性病毒性肝炎及HIV
Danae Bixler and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e951–e959, https://doi.org/10.1093/cid/ciaf730
32
Estimated Hepatitis C Prevalence and Viral Clearance Using Residual Sera From a Large Commercial Laboratory: November 2023–September 2024
利用大型商业实验室剩余血清估算丙型肝炎患病率及病毒清除率：2023年11月至2024年9月
Megan G Hofmeister and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e960–e966, https://doi.org/10.1093/cid/ciag007
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
33
State AIDS Drug Assistance Programs’Contribution to the US Viral Suppression, 2015–2022
美国各州艾滋病药物援助项目对全美病毒抑制的贡献，2015–2022年
Kathleen A McManus and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e967–e973, https://doi.org/10.1093/cid/ciag034
34
Centering AIDS Drug Assistance Programs in the US HIV Response
将艾滋病药物援助项目置于美国HIV应对的核心
Benjamin P Linas
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e974–e975, https://doi.org/10.1093/cid/ciag035
35
Association of Immunodeficiency and HIV Viremia With Cervical Precancer and Cancer Risk Among Women With HIV in South Africa
南非HIV感染女性中免疫缺陷和HIV病毒血症与宫颈癌前病变及癌症风险的关联
Yann Ruffieux and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e976–e983, https://doi.org/10.1093/cid/ciag093
36
Antiretroviral Activity, Pharmacokinetics, and Safety of MK-8527, an Oral Nucleoside Reverse Transcriptase Translocation Inhibitor, in Adults With HIV-1 Who Had Not Previously Taken Antiretroviral Agents: Results From 2 Open-Label, Phase 1 Studies
MK-8527（一种口服核苷逆转录酶转位抑制剂）在既往未接受过抗逆转录病毒治疗的HIV-1感染成人中的抗逆转录病毒活性、药代动力学及安全性：来自两项开放标签1期研究的结果
Russ P Carstens and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e984–e991, https://doi.org/10.1093/cid/ciag135
37
Point-of-Care Urine Tenofovir Drug-Level Feedback Counseling Improves Long-Term Pre-exposure Prophylaxis Adherence for US Men Who Have Sex With Men in Pilot RCT
床旁尿液替诺福韦药物浓度反馈咨询改善美国男男性行为者长期暴露前预防用药依从性——一项先导随机对照试验
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e992–e995, https://doi.org/10.1093/cid/ciag080
Mycobacterial Infections（分枝杆菌感染）
38
Diagnostic Accuracy of the STANDARD F TB-Feron FIA Assay for Tuberculosis Infection in Vietnam: A Cross-Sectional Study
STANDARD F TB-Feron FIA检测在越南结核感染诊断中的准确性：一项横断面研究
Han Thi Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e996–e1004, https://doi.org/10.1093/cid/ciaf561
39
Asymptomatic Tuberculosis in Children With Household Exposure to Mycobacterium tuberculosis
有结核分枝杆菌家庭接触史儿童中的无症状结核病
Humphrey Mulenga and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1005–e1013, https://doi.org/10.1093/cid/ciaf562
40
Insights into the Role of Rifampicin Exposure and Clinical Baseline Covariates on the Response to Pulmonary Tuberculosis Treatment
利福平暴露及临床基线协变量对肺结核治疗反应影响的深入认识
Marie Wijk and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1014–e1022, https://doi.org/10.1093/cid/ciaf586
41
Tuberculosis Infection Screening Recommendations for Targeted Immunotherapies: Comparison of US Prescribing Information, Clinical Resources, and Quality Measures
靶向免疫治疗的结核感染筛查建议：美国处方信息、临床资源与质量指标的比较
Matthew T Murrill and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1023–e1035, https://doi.org/10.1093/cid/ciaf628
42
Pharmacokinetics of Dexamethasone in Tuberculous Meningitis
地塞米松在结核性脑膜炎中的药代动力学
Jose M Calderin and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1036–e1042, https://doi.org/10.1093/cid/ciaf642
43
One Piece in the Puzzle of Tuberculous Meningitis: Dexamethasone Pharmacokinetics
结核性脑膜炎拼图中的一块：地塞米松药代动力学
Tjip S van der Werf and Marieke G G Sturkenboom
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1043–e1044, https://doi.org/10.1093/cid/ciaf644
44
Future Prospects for Using Clinical Phenotypes in Tuberculosis Precision Medicine—An Approach for Clinical Management
临床表型用于结核精准医学的未来前景——一种临床管理方法
Katarina Niward and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1045–e1052, https://doi.org/10.1093/cid/ciaf663
Pediatric and Maternal Infectious Diseases（儿科与孕产妇感染）
45
Maternal, Pregnancy, and Infant Outcomes in Women Treated for Multidrug-Resistant/Rifampicin-Resistant Tuberculosis With Novel and Repurposed Drugs in KwaZulu-Natal, South Africa
南非夸祖鲁-纳塔尔省接受新型及重新利用药物治疗耐多药/利福平耐药结核病的女性的母婴预后
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1053–e1062, https://doi.org/10.1093/cid/ciaf593
46
Pregnant Women With Multidrug-Resistant/Rifampicin-Resistant Tuberculosis and the All-Oral 6-Month Regimen: Experiences From a Patient Series in South Africa
南非耐多药/利福平耐药结核病孕妇与全口服6个月方案：一例系列患者的经验
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1063–e1071, https://doi.org/10.1093/cid/ciag032
47
Human Cytomegalovirus (HCMV) Shedding and T-cell Immune Responses in HCMV-seropositive Women During Pregnancy and Postpartum: Prevalence, Natural History, and Risk Factors
HCMV血清阳性女性孕期及产后人巨细胞病毒（HCMV）排毒和T细胞免疫应答：患病率、自然史及危险因素
Shari Sapuan and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1072–e1082, https://doi.org/10.1093/cid/ciag076
Vaccines（疫苗）
48
Safety and Immunogenicity of a Fourth Dose of Omicron BA.1–Adapted BNT162b2 COVID-19 Vaccines in Adults 18–55 Years Old
奥密克戎BA.1适配BNT162b2 COVID-19疫苗第四剂在18–55岁成人中的安全性和免疫原性
Patricia Winokur and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1083–e1092, https://doi.org/10.1093/cid/ciag026
49
Immunogenicity and Safety of the AS01E-adjuvanted Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine in Adults Aged 18–49 Years at Increased Risk of RSV Disease Compared with Adults Aged ≥60 Years
AS01E佐剂呼吸道合胞病毒（RSV）预融合F蛋白疫苗在18–49岁RSV高风险成人中与≥60岁成人的免疫原性和安全性比较
Essack Mitha and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1093–e1103, https://doi.org/10.1093/cid/ciag058
50
Real-World Effectiveness of RSVpreF and RSVpreF3 Vaccines in Preventing Hospitalization and Emergency Department Visits Associated With Respiratory Syncytial Virus in Older Adults: A Meta-analysis
RSVpreF和RSVpreF3疫苗在预防老年人RSV相关住院和急诊就诊中的真实世界有效性：一项荟萃分析
Dewan Md Sumsuzzman and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1104–e1111, https://doi.org/10.1093/cid/ciag107
51
Respiratory Syncytial Virus Vaccination in Solid Organ Transplant Recipients: Interim Findings From a Phase 3 Trial of mRNA-1345
实体器官移植受者的呼吸道合胞病毒疫苗接种：mRNA-1345三期试验中期结果
Erick F Mayer and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1112–e1121, https://doi.org/10.1093/cid/ciag108
Photo Quiz（影像问答）
52
Crusted, Chronic, and Confusing
结痂、慢性化与困惑
Luisa Hurtado-Rossi and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1122–e1125, https://doi.org/10.1093/cid/ciaf583
Correspondence（读者来信）
53
Unmasking the Hidden Guests: Referral and Secondary Infection Biases in Cutibacterium Endocarditis
揭开隐藏的访客：Cutibacterium心内膜炎中的转诊偏倚和二次感染偏倚
Shuo Li and Lin Wang
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1126, https://doi.org/10.1093/cid/ciaf733
54
Reply to Willoughby on the Demise of the Milwaukee Protocol for Rabies
对Willoughby关于密尔沃基狂犬病方案终结的回复
Alan C Jackson and Thiravat Hemachudha
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1126–e1127, https://doi.org/10.1093/cid/ciaf734
55
Estimating Vaccine Effectiveness Against Symptomatic Infection From Its Effectiveness Against Asymptomatic Infection
从无症状感染的疫苗有效性估算有症状感染的疫苗有效性
Eyal Shahar
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1127–e1128, https://doi.org/10.1093/cid/ciaf735
56
Contextualizing On-Therapy Resistance Development With Novel Antibiotics: Interplay Between Timing of Therapy Initiation and Critical Illness–Linked Pharmacokinetic/Pharmacodynamic Unpredictability
新型抗生素治疗中耐药产生的情境化解读：治疗启动时机与危重疾病相关药代动力学/药效学不可预测性之间的相互作用
Dilip Dubey and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1128–e1129, https://doi.org/10.1093/cid/ciag010
57
The Clinical Thermometer as the First Home Test for Infectious Disease
临床体温计：感染性疾病的首个家用检测工具
Michele Augusto Riva
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1129–e1130, https://doi.org/10.1093/cid/ciag030
58
Methodology Misrepresented: Correcting the Record on the American Thoracic Society Community-acquired Pneumonia Guideline Process
方法论被歪曲：更正美国胸科学会社区获得性肺炎指南制定过程的记录
Kevin C Wilson and Eyal Oren
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1130–e1131, https://doi.org/10.1093/cid/ciag040
59
Misleading Comments About the Impact of Early Bacillus Calmette-Guerin Vaccination on Neonatal and Infant Mortality
关于早期卡介苗接种对新生儿和婴儿死亡率影响的误导性评论
Peter Aaby and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1131–e1132, https://doi.org/10.1093/cid/ciag065
60
Questioning Non-inferiority: Methodological Concerns in the Meta-analysis of Oral vs Intravenous Therapy for Staphylococcus aureus Bacteremia
质疑非劣效性：金黄色葡萄球菌菌血症口服与静脉治疗荟萃分析中的方法学问题
Dawd S Siraj and Fauzia Hollnagel
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1132–e1133, https://doi.org/10.1093/cid/ciag070
61
Problems With Electronic Health Record Penicillin Allergy Mislabeling and Recommendations for Their Correction
电子健康记录中青霉素过敏标注错误的问题及纠正建议
David J Witt and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Page e1134, https://doi.org/10.1093/cid/ciag086
62
Complex Problem, Digital Cure? Rethinking Penicillin Allergy Relabeling Using Technology-Enabled Care
复杂问题，数字解药？利用技术赋能护理重新思考青霉素过敏重新标注
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 5, 15 May 2026, Pages e1135–e1137, https://doi.org/10.1093/cid/ciag084
Clinical Infectious Diseases Volume 82 Issue Supplement_5
临床传染病学 82卷 增刊5期
https://academic.oup.com/cid/issue/
SUPPLEMENT（增刊）
ADVANCE-ID: Conducting Innovative Clinical Trials and Promoting Access for Antibiotics in Asia
ADVANCE-ID：在亚洲开展创新临床试验并推动抗生素可及性
SUPPLEMENT ARTICLES（增补论著）
1
Advancing Clinical Evidence in Infectious Diseases: An Infectious Diseases Clinical Trials Network for Asia, the “Antimicrobial Resistance Hot Zone”
推进感染病临床证据：面向亚洲——这一"耐药热点区域"——的感染性疾病临床试验网络
David L Paterson
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S101–S104, https://doi.org/10.1093/cid/ciag122
2
Global Survey on the Management of Multidrug-resistant Gram-negative Bacilli: Divergence of Practice Between High-Income Countries and the Rest of the World
多重耐药革兰阴性杆菌管理的全球调查：高收入国家与世界其他地区的实践差异
Abi Manesh and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S105–S115, https://doi.org/10.1093/cid/ciag025
3
Efficacy and Safety of Newer Antibiotics Versus Generic Antibiotics for Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia: A Systematic Review and Meta-analysis of Randomized Controlled Trials
新型抗生素与仿制抗生素治疗医院获得性及呼吸机相关性细菌性肺炎的疗效与安全性：随机对照试验的系统综述与荟萃分析
Anh T K Nguyen and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S116–S125, https://doi.org/10.1093/cid/ciag045
4
Antibiotic Clinical Trials: A Review of the Past, Present Challenges, and Potential Solutions
抗生素临床试验：回顾过去、当前挑战及潜在解决方案
Melissa J Hardy and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S126–S137, https://doi.org/10.1093/cid/ciag017
5
Considerations in Designing Clinical Trials of Novel Antibacterial Agents Using a Superiority Design
采用优效性设计开展新型抗菌药物临床试验的考量
David L Paterson and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S138–S146, https://doi.org/10.1093/cid/ciag207
6
Consent Modes and Consent Rates in Randomized Controlled Trials for Severe Infections: A Scoping Review
严重感染随机对照试验中的知情同意方式与同意率：范围性综述
Yiyun Shou and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S147–S153, https://doi.org/10.1093/cid/ciaf715
7
Challenges to Accessing Newer Antibiotics for Multidrug-resistant Bacterial Infections in Asia: A Literature Review of Multi-Stakeholder Perspectives
亚洲多重耐药细菌感染中获取新型抗生素的挑战：多利益相关方视角的文献综述
Alec F Aligui and others
Clinical Infectious Diseases, Volume 82, Issue Supplement_5, 15 June 2026, Pages S154–S161, https://doi.org/10.1093/cid/ciag024
Clinical Infectious Diseases Volume 82 Issue 6
临床传染病学 82卷 6期
https://academic.oup.com/cid/issue/
ID Art Through the Ages（传染病艺术长河）
1
Cover Illustration for Camus' The Plague, 1948
加缪《鼠疫》封面插画，1948年
Michael B Grizzard and Mary Grizzard
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page i, https://doi.org/10.1093/cid/ciag182
In the Literature（文献札记）
2
In the Literature
文献札记
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages ii–v, https://doi.org/10.1093/cid/ciag181
State-of-the-Art Review（前沿综述）
3
State-of-the-Art Review: Contemporary Ambulatory Approach to Adult Fever of Unknown Origin
前沿综述：成人不明原因发热的当代门诊诊疗方案
William F Wright and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 909–926, https://doi.org/10.1093/cid/ciag158
Ethics Rounds（伦理巡诊）
4
Antibiotics in Hospice: Applying the Four-Quadrant Approach to Improve Patient-Centered Care
安宁疗护中的抗菌药物使用：运用四象限诊疗模式优化以患者为中心的照护
Patrick D Crowley and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 927–930, https://doi.org/10.1093/cid/ciag057
Voices of ID（传染病之声）
5
I Died—and Was Brought Back to Life—Twice
我两次濒死，又重获新生
Richard E. Sutton
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 931–933, https://doi.org/10.1093/cid/ciaf612
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
6
Using Encounter-Level Data for Risk-Adjustment of Antimicrobial Use Comparisons: Feasibility and Variable Selection
利用就诊层面数据开展抗菌药物使用对比的风险校正：可行性与变量筛选研究
Rebekah W Moehring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 934–943, https://doi.org/10.1093/cid/ciaf682
7
Moving Closer to Patient-Level Risk Adjustment for Hospital Antimicrobial Use
推进住院患者抗菌药物使用的个体化风险校正体系构建
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 944–945, https://doi.org/10.1093/cid/ciaf683
8
Macrolide and Nonmacrolide Resistance After 36 Months of Mass Azithromycin Distribution in Burkina Faso: A Cluster Randomized Trial
布基纳法索大规模阿奇霉素分发36个月后大环内酯类与非大环内酯类耐药情况：一项整群随机对照试验
Catherine E Oldenburg and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 946–953, https://doi.org/10.1093/cid/ciag051
9
Using Probability of Community-Acquired Pneumonia to Tailor Antimicrobials Among Inpatients: A Pragmatic, Randomized Trial
基于社区获得性肺炎发病概率为住院患者个体化选用抗菌药物：一项实用性随机对照试验
Jonathan D Baghdadi and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 954–961, https://doi.org/10.1093/cid/ciag126
10
ALARA in Antimicrobial Stewardship: Adapting Radiation Safety Principles to Address Antibiotic Overuse
抗菌药物管理中的ALARA原则：借鉴辐射安全理念管控抗生素过度使用
Zachary T Aldewereld and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 962–967, https://doi.org/10.1093/cid/ciaf688
Clinical Practice and Policy（临床实践与医疗政策）
11
Assessment of an Infectious Disease eConsult Service at a Large Mid-Atlantic Healthcare System
美国中大西洋大型医疗体系感染病线上会诊服务应用效果评估
Ava Hunt and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 968–970, https://doi.org/10.1093/cid/ciaf736
12
H.U.S.T.L.E: A Consult Fitness Guide for Infectious Diseases Providers
H.U.S.T.L.E指南：感染科医师会诊工作实操指南
Gonzalo Bearman and Priya Nori
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 971–975, https://doi.org/10.1093/cid/ciaf672
13
More Than a Message: Death by a 1000 “Chats”
不止简单文字沟通：无休止线上问诊带来的诊疗困境
Darcy Wooten and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 976–978, https://doi.org/10.1093/cid/ciag094
14
The Erosion of a Pillar of Public Health: ACIP's Role and the Future of US Vaccine Policy Post-June 2025
公共卫生支柱职能削弱：美国免疫实践咨询委员会的职能变迁与2025年6月后疫苗政策走向
Edwin J Asturias and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 979–985, https://doi.org/10.1093/cid/ciag042
15
Worldwide Impact of ACIP's 2025 Overhaul
2025年美国免疫实践咨询委员会政策修订的全球影响
Louis Bont and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 986–987, https://doi.org/10.1093/cid/ciag043
Hepatitis（肝炎）
16
Trends in Reflexive Hepatitis C Virus Testing in a National US Laboratory: A Retrospective Study From 2018 to 2024
美国国家级实验室丙型肝炎病毒 reflex联动检测趋势：2018–2024年回顾性研究
Min Kyung Lee and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 988–992, https://doi.org/10.1093/cid/ciag227
17
Sofosbuvir/Velpatasvir Concentrations in the Breastmilk of Postpartum Women With Opioid Use Disorder Receiving Treatment for Hepatitis C Virus: A Pharmacokinetic Study
合并阿片类物质使用障碍的产后丙肝治疗女性母乳中索磷布韦/维帕他韦药物浓度：药代动力学研究
Catherine A Chappell and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 993–996, https://doi.org/10.1093/cid/ciaf443
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
18
Incidence of Community-acquired Pneumonia and Herpes Zoster in People With HIV Based on CD4 Count and Age in the Current Antiretroviral Therapy Era: A Longitudinal Cohort Study
当前抗逆转录病毒治疗时代，基于CD4计数与年龄划分的HIV感染者社区获得性肺炎、带状疱疹发病风险：一项纵向队列研究
Elsemieke te Linde and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 997–1006, https://doi.org/10.1093/cid/ciaf686
19
Switch to Bictegravir/Tenofovir Alafenamide/Emtrictabine or Dolutegravir + Tenofovir Disoproxil Fumarate/Emtrictabine in Virologically Suppressed People With HIV: Outcomes in Real-world Setting With and Without Tenofovir Resistance
病毒学抑制HIV感染者转换为比克替拉韦/丙酚替诺福韦/恩曲他滨方案或多替拉韦+富马酸替诺福韦二吡呋酯/恩曲他滨方案：有无替诺福韦耐药人群真实世界转归
Alain Makinson and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1007–1014, https://doi.org/10.1093/cid/ciaf726
20
Hepatitis B Outcomes After Switching to Long-Acting Cabotegravir/Rilpivirine in People With HIV: Reactivation, Incident Infection, and Liver Safety Across Diverse Serological Profiles
HIV感染者转换长效卡博特韦/利匹韦林后的乙肝转归：病毒再激活、新发感染及不同血清学状态下肝脏安全性
Alberto Foncillas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1015–1022, https://doi.org/10.1093/cid/ciag023
21
Virological Failure on Long-Acting Injectable Cabotegravir and Rilpivirine: An Analysis of Subtypes, Drug Levels, Resistance, and Therapeutic Implications
长效注射卡博特韦联合利匹韦林治疗发生病毒学失败：亚型、血药浓度、耐药突变及临床诊疗意义分析
Maria Mazzitelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1023–1031, https://doi.org/10.1093/cid/ciag046
22
What Are the Causes and Consequences of Virological Failure on Long-acting Cabotegravir/Rilpivirine?
长效卡博特韦/利匹韦林方案病毒学失败的诱因与临床后果
Andrew Hill and Chloe Orkin
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1032–1034, https://doi.org/10.1093/cid/ciag047
Parasitic Infections（寄生虫感染）
23
Cerebral Malaria and Severe Malarial Anemia, but not Other Forms of Severe Malaria, Are Associated With Long-Term Cognitive Impairment
脑型疟疾与重症疟疾性贫血（其余重症疟疾亚型除外）与远期认知损伤相关
Paul Bangirana and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1035–1041, https://doi.org/10.1093/cid/ciaf712
24
Not All Forms of Severe Malaria Impair Long-term Cognition—More Characterization, More Questions
并非所有重症疟疾均会造成长期认知损害——仍需更多分层研究与探索
Karl B Seydel and Stephen T J Ray
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1042–1043, https://doi.org/10.1093/cid/ciaf713
25
Frequent Plasmodium ovale Recurrence in Coastal Tanzania
坦桑尼亚沿海地区卵形疟原虫高复发率研究
Kelly Carey-Ewend and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1044–1051, https://doi.org/10.1093/cid/ciag199
26
Invisible Malarias
隐匿性疟疾
J Kevin Baird
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1052–1053, https://doi.org/10.1093/cid/ciag201
Sexually Transmitted Infections（性传播疾病）
27
A Pilot, Randomized Controlled Trial of Dual Daily HIV and Sexually Transmitted Infection Pre-exposure Prophylaxis Using Tenofovir Disoproxil Fumarate/Emtricitabine and Doxycycline in Gay, Bisexual, and Other Men Who Have Sex With Men and Transgender Women: The DuDHS Study
男男性行为人群及跨性别女性每日口服HIV联合性病暴露前预防（富马酸替诺福韦二吡呋酯/恩曲他滨加多西环素）先导随机对照试验：DuDHS研究
Troy Grennan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1054–1062, https://doi.org/10.1093/cid/ciaf043
28
A New Choice for Doxycycline Prophylaxis
多西环素暴露前预防新选择
Jeffrey D Klausner
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1063–1064, https://doi.org/10.1093/cid/ciaf044
29
Antimicrobial-Resistant Neisseria gonorrhoeae Infections in Men Using Doxycycline Postexposure Prophylaxis: A Substudy of the ANRS 174 DOXYVAC Trial
服用多西环素暴露后预防男性的耐药淋病奈瑟菌感染情况：ANRS 174 DOXYVAC子研究
Béatrice Berçot and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1065–1074, https://doi.org/10.1093/cid/ciaf591
30
Sustained Effectiveness of Doxycycline Post-Exposure-Prophylaxis in a Large Sexual Health Clinic Over 96 Weeks: An Interrupted Time Series Analysis
大型性病诊疗中心多西环素暴露后预防96周持续有效率：间断时间序列分析
Matthew A Spinelli and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1075–1078, https://doi.org/10.1093/cid/ciaf234
Photo Quiz（影像问答）
31
A 3-Year-Old Girl With a Chest Wall Mass
3岁女童胸壁肿块一例
Deema Gashgarey and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1079–1081, https://doi.org/10.1093/cid/ciag028
32
Why Are Gonorrhea Case Rates Declining in the United States? A Research Agenda
美国淋病报告病例数下降原因：后续研究方向展望
Kirstin I Oliveira Roster and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1082–1090, https://doi.org/10.1093/cid/ciaf690
33
Fever in a Man with Uncontrolled HIV
HIV控制不佳男性发热病例
Tristan Jones and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages 1091–1095, https://doi.org/10.1093/cid/ciag056
Antimicrobial Resistance and Stewardship（抗生素耐药与管理）
34
Human Cases of Carbapenemase-Producing Escherichia coli Linked to Spread Between Animals and the Environment in a Veterinary Facility—Massachusetts, USA, 2023
2023年美国马萨诸塞州：动物诊疗机构内动物与环境传播引发人感染产碳青霉烯酶大肠埃希菌病例
Ian M DeStefano and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1138–e1144, https://doi.org/10.1093/cid/ciaf541
35
Carbapenemase-Producing Enterobacterales in Pets: A New Threat From Veterinary Clinics
宠物携带产碳青霉烯酶肠杆菌目细菌：动物诊所带来的新型感染威胁
Vincent Perreten and Andrea Endimiani
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1145–e1147, https://doi.org/10.1093/cid/ciaf544
36
Direct Oral Challenge for Penicillin Allergy: The International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服药物激发试验：国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1148–e1162, https://doi.org/10.1093/cid/ciag082
37
Direct Oral Challenge for Penicillin Allergy: A Hospital Implementation Evaluation Via the International Network of Antibiotic Allergy Nations (iNAAN) Study
青霉素过敏口服激发试验院内落地实施效果评估——基于国际抗生素过敏协作网络（iNAAN）研究
Elise A Mitri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1163–e1170, https://doi.org/10.1093/cid/ciag083
Bacterial Infections（细菌感染）
38
Clinical Manifestations, Long-Term Trends, and Risk Factors for Treatment Failure in Native Vertebral Osteomyelitis: A 26-Year Mayo Clinic Experience
原发性椎体骨髓炎临床表现、26年长期发病趋势及治疗失败危险因素：梅奥诊所单中心经验
Takahiro Matsuo and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1171–e1180, https://doi.org/10.1093/cid/ciag048
39
The Management of Native Vertebral Osteomyelitis Remains Unchanged: Are Additional Trials Necessary?
原发性椎体骨髓炎诊疗方案无实质性更新：是否仍需开展更多临床试验？
Werner Zimmerli
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1181–e1183, https://doi.org/10.1093/cid/ciag049
40
Clinical Characteristics and Survival of Hospitalized Anthrax Patients with Pleural, Pericardial, or Peritoneal Fluid Collections
合并胸腔、心包、腹腔积液的住院炭疽患者临床特征与生存预后
Jon-Erik C Holty and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1184–e1193, https://doi.org/10.1093/cid/ciag113
41
Uncomplicated Urinary Tract Infections: From an Invisible Impact to a Visible Change in Complex Care
单纯性尿路感染：从隐匿疾病负担到复杂诊疗体系的诊疗变革
Rafael Cantón and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1194–e1199, https://doi.org/10.1093/cid/ciaf705
Emerging Infections（新型感染）
42
Six Cases of Borealpox and Evidence of a Zoonotic Source: Alaska, 2020–2023
2020–2023年阿拉斯加6例北极痘病例及动物源性传播证据
Eric Q Mooring and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1200–e1207, https://doi.org/10.1093/cid/ciaf497
43
Measles Without Rash During Acute Febrile Illness Surveillance in Tanzania, 2023–2024
2023–2024年坦桑尼亚急性发热监测中无皮疹麻疹病例
Saning'o Lukumay and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1208–e1215, https://doi.org/10.1093/cid/ciaf582
44
Melioidosis Complicated by Native Valve Endocarditis in a Traveler Returning From Thailand to the United States
泰国归国旅行者罹患类鼻疽合并原生瓣膜心内膜炎
Akash Gupta and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1216–e1221, https://doi.org/10.1093/cid/ciag003
HIV/AIDs（人类免疫缺陷病毒/艾滋病）
45
Hepatocellular Carcinoma Survival in People With and Without HIV in the United States, 2001–2019
2001–2019年美国HIV阳性与阴性人群肝细胞癌生存预后对比
Jennifer K McGee-Avila and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1222–e1231, https://doi.org/10.1093/cid/ciag137
46
Risk of Major Adverse Cardiovascular Events With Dolutegravir Versus Efavirenz-Based Antiretroviral Therapy: Emulated Target Trials Using Routine, De-identified Data From South Africa
多替拉韦方案对比依非韦伦方案抗逆转录病毒治疗重大心血管不良事件风险：基于南非匿名常规医疗数据的模拟目标试验
Jienchi Dorward and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1232–e1241, https://doi.org/10.1093/cid/ciag155
47
Patterns of HIV-1 Viral Load Suppression and Drug Resistance During the Dolutegravir Transition: A Population-based Longitudinal Study
全面切换多替拉韦治疗期间HIV-1病毒载量抑制水平与耐药突变特征：一项人群纵向研究
Michael A Martin and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1242–e1251, https://doi.org/10.1093/cid/ciag161
48
Renal and Cardiovascular Complications Following Type 2 Diabetes Mellitus in People With and Without HIV: Data From the Cohort Study on Morbidity and HIV in Sweden (COSMOHS) Between 2010 and 2024
合并2型糖尿病的HIV感染者与非感染者肾脏及心血管并发症：瑞典HIV发病队列研究（COSMOHS）2010–2024数据
Isabela Killander Möller and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1252–e1261, https://doi.org/10.1093/cid/ciag261
49
Progression Risk in Cancer Patients with HIV Compared with Cancer Patients Without HIV
HIV阳性肿瘤患者相较于阴性患者的疾病进展风险
Derek Schneider and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1262–e1265, https://doi.org/10.1093/cid/ciag170
Infections in Older Adults（老年人群感染）
50
Burden of Respiratory Syncytial Virus Among Older Adults With an Acute Respiratory Infection: A Prospective Study in Six European Countries
急性呼吸道感染老年患者呼吸道合胞病毒疾病负担：欧洲六国前瞻性研究
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1266–e1276, https://doi.org/10.1093/cid/ciag146
51
Health-related Quality of Life in European Older Adults with Respiratory Syncytial Virus Over Three Respiratory Syncytial Virus Seasons
连续三个流行季欧洲老年呼吸道合胞病毒感染者健康相关生活质量调查
Manel Terns Riera and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1277–e1288, https://doi.org/10.1093/cid/ciag147
52
The Renaissance of Respiratory Syncytial Virus Diagnosis: How Understanding Burden Can Inform Clinical Practice and Demonstrate the Benefit of Vaccines
呼吸道合胞病毒诊断技术革新：明晰疾病负担指导临床实践、印证疫苗获益价值
Angela R Branche
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1289–e1291, https://doi.org/10.1093/cid/ciag148
Mycobacterial Infections（分枝杆菌感染）
53
Hidden in Success: Gendered Patterns of Suboptimal Care Engagement Among Tuberculosis Patients Who“Successfully” Completed Treatment in South Africa
治愈背后的隐忧：南非“治疗成功”结核患者就医依从性的性别差异
Andrew Medina-Marino and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1292–e1301, https://doi.org/10.1093/cid/ciaf714
54
Prevalence and Predictors of Tuberculosis in Adults and Adolescents With Sputum Trace Ultra Results in 2 High-Burden Clinical Settings
两大高结核负担临床中心痰Xpert Ultra微量阳性成人及青少年结核患病率与预测因素
Caitlin Visek and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1302–e1310, https://doi.org/10.1093/cid/ciag019
55
“Trace-MTB” on Sputum Xpert Ultra: New Evidence for Interpretation in High-burden Settings
痰Xpert Ultra“微量结核分枝杆菌”阳性：高结核负担地区判读新证据
Bianca Sossen and Neil Martinson
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1311–e1312, https://doi.org/10.1093/cid/ciag018
56
Diagnostic Accuracy of Molecular Testing on Saliva and Oral Swabs for Pulmonary Tuberculosis
唾液与口腔拭子分子检测对肺结核的诊断效能
Deninson Alejandro Vargas and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1313–e1321, https://doi.org/10.1093/cid/ciag055
57
Documenting Environmentally Acquired Mycobacterium intracellulare subsp. chimaera Pulmonary Disease Soon After Bronchiectasis Onset
支气管扩张发病后短期内确诊环境源性奇美拉胞内分枝杆菌肺病病例报道
Jennifer R Honda and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1322–e1325, https://doi.org/10.1093/cid/ciag015
58
We Are Underprepared for Bedaquiline Resistance: A Call for Clinical and Programmatic Readiness
我国对贝达喹啉耐药危机应对准备不足：呼吁完善临床与公共卫生防控体系
Gail Brenda Cross and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1326–e1332, https://doi.org/10.1093/cid/ciag008
Respiratory Infections（呼吸道感染）
59
Long-term Clinical Outcomes After Hospitalization for Acute Respiratory Illness Due to Respiratory Syncytial Virus
呼吸道合胞病毒急性呼吸道感染住院患者远期临床结局
David Singer and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1333–e1344, https://doi.org/10.1093/cid/ciaf710
60
Microbial Detection in Community-Acquired Pleural Space Infections Using the BIOFIRE Joint Infection Panel and Individual Polymerase Chain Reaction Assays
采用BIOFIRE关节感染试剂盒与单重PCR检测社区获得性胸腔感染病原体
Portia Mira and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1345–e1352, https://doi.org/10.1093/cid/ciag050
61
Diagnostic Performance of New Commercial Interferon-Gamma Release Assays for Mycobacterium tuberculosis Infection: An Updated Systematic Review and Meta-analysis
新型商业化γ干扰素释放试验诊断结核分枝杆菌感染的效能：更新系统综述与荟萃分析
Lika Apriani and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1353–e1364, https://doi.org/10.1093/cid/ciag102
Viral Infections（病毒感染）
62
Symptomatic and Asymptomatic Norovirus Infections in Early Life; the PREVAIL Cohort, 2017–2020
婴幼儿诺如病毒显性与隐性感染：PREVAIL队列2017–2020年数据
Julia M Baker and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1365–e1374, https://doi.org/10.1093/cid/ciag033
63
Age-Specific Risk of Herpes Zoster in Adults Aged ≥18 Years With Comorbid Conditions—A Retrospective Cohort Study in the United States
≥18岁合并基础疾病成人带状疱疹分年龄发病风险：美国回顾性队列研究
Rachel A Cohen and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1375–e1383, https://doi.org/10.1093/cid/ciag095
64
Herpes Simplex Virus Type 1 Encephalitis: A Prospective Population-Based Cohort Study
1型单纯疱疹病毒性脑炎：一项基于人群的前瞻性队列研究
Lærke Storgaard Duerlund and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1384–e1392, https://doi.org/10.1093/cid/ciag136
Photo Quiz（影像问答）
65
Multifocal Cutaneous Abscesses
多发皮肤脓肿病例
Shrruthi Velavan and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1393–e1396, https://doi.org/10.1093/cid/ciag074
Correspondence（读者来信）
66
New French Guidelines on Subcutaneous Antibiotic Therapy: A Response to Di Bella et al.
法国皮下注射抗生素新版指南发布——回应Di Bella等人研究
Emmanuel Forestier and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1397–e1398, https://doi.org/10.1093/cid/ciag088
67
Time to Appropriate Therapy and Antimicrobial Resistance-Attributable Mortality
抗菌药物及时给药时长与耐药相关死亡风险
Tatsuhiko Nanri and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1398, https://doi.org/10.1093/cid/ciag087
68
Is Time to Appropriate Therapy a Mediator of Mortality Associated With Antimicrobial Resistance?
抗菌药物及时给药时长是否介导耐药相关死亡风险？
Kevin A Brown and Nick Daneman
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1398–e1399, https://doi.org/10.1093/cid/ciag090
69
Request for Additional Details on the COPAT Trial
恳请补充COPAT试验详细研究数据
Brad Spellberg and Bassam Ghanem
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1399, https://doi.org/10.1093/cid/ciag100
70
Additional Details on the COPAT Trial
COPAT试验补充研究细节回复
Joy J Juskowich and Arif R Sarwari
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1399–e1401, https://doi.org/10.1093/cid/ciag103
71
Zinc: An Oft-forgotten Component in the Management of Diarrhea
锌剂：腹泻治疗中常被忽视的关键药物
Indi Trehan
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Page e1401, https://doi.org/10.1093/cid/ciag111
72
I Zinc, Therefore I Am: Context is Key
锌剂不可或缺：临床应用需结合具体场景
Andi L Shane and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1401–e1402, https://doi.org/10.1093/cid/ciag112
73
When IS900 Positivity is not the Tie-Breaker: Interpreting Mycobacterium avium Subspecies paratuberculosis Signals Across Crohn's Disease and Intestinal Tuberculosis in a Tuberculosis-Endemic Setting
IS900阳性结果不可作为鉴别金标准：结核高发区克罗恩病与肠结核中副结核分枝杆菌判读要点
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1402–e1403, https://doi.org/10.1093/cid/ciag127
74
MAP Detection: Identifying a Pathogenic Driver Rather Than a Diagnostic Marker
副结核分枝杆菌检测：识别致病驱动因素而非单纯诊断标志物
Sudheer Kumar Vuyyuru and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1403–e1405, https://doi.org/10.1093/cid/ciag128
75
Composite End Points, Minor Anomalies, and Missed Work-Ups: Making 12-Month Infant “Unfavorable Outcomes” Interpretable After BDLLfx/BDLCfz in Pregnancy
复合终点、轻微异常与漏诊评估：解读孕期BDLLfx/BDLCfz方案暴露婴儿12个月不良结局
Yuanli Yang
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1405–e1406, https://doi.org/10.1093/cid/ciag142
76
Responding Appropriately to Safety Signals in Infants Exposed to the 6-month BDLLfx/BDLCfz Regimen In Utero
妥善处置宫内暴露6个月BDLLfx/BDLCfz方案婴儿的安全预警信号
Marian Loveday and others
Clinical Infectious Diseases, Volume 82, Issue 6, 15 June 2026, Pages e1406–e1407, https://doi.org/10.1093/cid/ciag143
2026-08-09
·药策论讯
批准情况汇总
表格
国家/地区药品名称活性成分批准日期持证商适应症作用机制🇨🇳 NMPAoreporexton（TAK-861）oveporexton2026/8月初武田制药成人1型发作性睡病（NT1）中国全球首批，首个口服orexin受体2（OX2R）选择性激动剂，直接恢复orexin信号传导🇨🇳 NMPA替恩戈替尼片（捷恩泰®）替恩戈替尼2026/8月药捷安康FGFR2融合/重排晚期胆管癌（三线，附条件批准）FGFR抑制剂，ORR 28.0%，mPFS 6.0个月，mOS 20.7个月🇨🇳 NMPA瑞康曲妥珠单抗（SHR-A1811）瑞康曲妥珠单抗2026/8月恒瑞医药HER2阳性结直肠癌（奥沙利铂/氟尿嘧啶/伊立替康治疗失败后）HER2靶向ADC，首款获批治疗结直肠癌的ADC🇨🇳 NMPA艾玛昔替尼片艾玛昔替尼2026/8月恒瑞医药活动性放射学阴性中轴型脊柱关节炎（nr-axSpA）（第五适应症）JAK1选择性抑制剂🇺🇸 FDAOrzeyful™oveporexton2026/8/5Takeda成人1型发作性睡病（NT1）全球首个口服orexin受体2（OX2R）选择性激动剂，直接恢复orexin信号传导🇺🇸 FDATudriqev™vusolimogene oderparepvec-wtpg2026/8/6ReplimunePD-1治疗后进展的不可切除晚期皮肤黑色素瘤（联合nivolumab）基因改造溶瘤病毒免疫疗法，瘤内注射联合PD-1抗体🇺🇸 FDAmFLUSIVA™mRNA-10102026/8/6Moderna50岁及以上成人季节性流感预防全球首款mRNA技术平台流感疫苗，三价mRNA（各12.5μg）🇺🇸 FDAPluvicto®lutetium Lu 177 vipivotide tetraxetan2026/8/3NovartisPSMA阳性转移性激素敏感性前列腺癌（mHSPC）（扩展适应症）PSMA靶向放射性配体疗法（RLT），联合ARPI🇪🇺 ECJascayd™nerandomilast2026/8/4Boehringer Ingelheim特发性肺纤维化（IPF）和进展性肺纤维化（PPF）口服磷酸二酯酶4B（PDE4B）选择性抑制剂🇪🇺 ECMenQuadfi®脑膜炎球菌ACWY结合疫苗2026/8/4Sanofi扩展适应症：最小接种年龄延伸至6周龄婴儿四价脑膜炎球菌结合疫苗
EMA CHMP于7月会议推荐12种新药获批（详见第四节），包括Icotyde（全球首个口服IL-23受体拮抗剂）、Susvimo（欧盟首个可填充眼内植入剂）等重磅品种。
本周NMPA创新药品名录尚未更新至8月批准数据（截至8月8日最新公示日为7月29日）。但据多方报道，武田oveporexton已在中国率先获得NMPA全球首批上市许可，中国成为全球首个批准该药的国家。
一、中国NMPA
oreporexton（TAK-861）——中国全球首批，首个orexin受体激动剂
批准日期：2026年8月初（NMPA全球首批，早于FDA 8月5日批准）持证商：武田制药（Takeda）注册分类：1类创新药（优先审评）适应症：成人1型发作性睡病（NT1，伴猝倒发作性睡病），据报也覆盖16岁以上青少年作用机制：口服orexin受体2（OX2R）选择性激动剂。直接激活OX2R恢复缺失的orexin信号传导，从疾病根本病因层面治疗NT1，而非使用兴奋剂或镇静剂仅针对症状临床数据：基于两项全球多中心、随机、双盲、安慰剂对照12周III期研究（FirstLight/NCT06470828和RadiantLight/NCT06505031），共入组273例NT1成人患者。oreporexton 2mg BID组在MWT（维持觉醒测试）主要终点显著优于安慰剂（P<0.001），ESS评分显著降低，每周猝倒发作频率显著减少（P<0.001），同时改善睡眠瘫痪、幻觉和夜间睡眠碎片化。II期数据显示MWT提升12.5-25.4分钟（安慰剂-1.2分钟），呈剂量依赖性临床意义：中国NMPA全球首批——标志着中国在全球创新药审评速度上的重大突破。NT1为罕见神经系统疾病，美国约12万患者，中国已纳入《第二批罕见病目录》。此前全球无任何药物获批用于NT1的整体治疗，oreporexton是首个也是唯一直接靶向orexin信号缺失的创新药。武田 orexin管线还包括TAK-360（NT1/NT2/特发性嗜睡症）和TAK-495原文网址：https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/index.html （NMPA创新药品名录尚未更新，待公示后补充具体链接）
二、美国FDA
1. Orzeyful™（oveporexton）——首个orexin受体激动剂，重新定义发作性睡病治疗
批准日期：2026年8月5日持证商：Takeda Pharmaceuticals America, Inc.注册分类：Novel Drug（1类创新药），突破性疗法认定+优先审评适应症：成人1型发作性睡病（narcolepsy type 1, NT1，伴猝倒症）作用机制：口服orexin受体2（OX2R）选择性激动剂，选择性激活OX2R恢复缺失的orexin信号传导，促进觉醒并减少异常REM睡眠现象（包括猝倒），从而全面改善NT1的日间和夜间症状。区别于此前所有以兴奋剂或镇静剂对症治疗的方案，oreporexton首次直接靶向疾病根本病因临床数据：两项III期研究（FirstLight和RadiantLight），273例NT1成人。主要终点MWT显著改善（P<0.001，两项研究均达成）。次要终点ESS评分显著降低、每周猝倒频率显著减少（P<0.001），并在睡眠瘫痪、幻觉和夜间睡眠碎片化方面均有显著改善。II期数据（NEJM发表）：MWT改善12.5-25.4分钟vs安慰剂-1.2分钟（P≤0.001）。JAMA Neurology发表的认知亚组分析显示注意力、记忆力和执行功能中等到大幅度改善临床意义：全球首个获批的orexin受体激动剂，首个也是唯一获批用于NT1整体治疗的药物。NT1影响美国约12万人（全球约1/2000），由orexin神经元不可逆缺失引起，导致日间过度嗜睡、猝倒、睡眠瘫痪、入睡前幻觉和夜间睡眠紊乱。此前无任何药物获批用于NT1的整体治疗，只能分别使用兴奋剂（控制嗜睡）和羟丁酸钠（控制猝倒）等对症药物。oreporexton的获批标志着从"症状拼凑管理"到"病因靶向整体治疗"的范式转变。DEA管制物质分类审查中，预计90天内完成原文网址：https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptoms
2. Tudriqev™（vusolimogene oderparepvec-wtpg）——首款溶瘤病毒免疫疗法获批治疗黑色素瘤
批准日期：2026年8月6日（加速批准）持证商：Replimune, Inc.注册分类：Novel Drug（1类创新药），突破性疗法认定+加速批准适应症：联合nivolumab治疗抗PD-1抗体方案治疗后进展的不可切除晚期皮肤黑色素瘤成人患者作用机制：基因改造的溶瘤病毒免疫疗法（oncolytic viral therapy） 。经基因改造的单纯疱疹病毒1型（HSV-1），在肿瘤细胞内选择性复制并裂解肿瘤细胞，同时释放肿瘤相关抗原和促炎因子，激发全身抗肿瘤免疫应答。与nivolumab（PD-1抗体）联用，通过"冷肿瘤转热"机制克服PD-1耐药临床数据：基于IGNITE研究（NCT03767348），开放标签、多区域、单臂试验，140例IIIB/IIIC/IV期不可切除晚期黑色素瘤患者（均经≥8周抗PD-1治疗后进展）。疗效可评估人群91例（至少有一个非注射病灶）。ORR 24.2%（95%CI 15.8-34.3），中位DOR 14.1个月（10.7-未达到）。此前该申请两次被FDA拒绝（2024年和2025年），2026年7月30日CTGTAC以10:3投票支持疗效可评估且有临床意义后获批临床意义：全球首款获批的基因改造溶瘤病毒联合PD-1抗体用于PD-1耐药后黑色素瘤的疗法。该药获批之路坎坷——此前两次FDA拒绝后最终凭借患者社区强烈支持和肿瘤学专家力挺获批。分析师预计峰值销售额可达13亿美元。瘤内注射给药方式使其适用于门诊治疗。Replimune正规划上市后确证性试验以维持加速批准原文网址：https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanoma
3. mFLUSIVA™（mRNA-1010）——全球首款mRNA流感疫苗获批上市
批准日期：2026年8月6日持证商：Moderna, Inc.注册分类：疫苗（非传统Novel Drug），突破性技术平台适应症：50岁及以上成人季节性流感预防作用机制：mRNA技术平台流感疫苗。三价mRNA疫苗（37.5μg，含A/H1N1、A/H3N2、B/Victoria各12.5μg），编码流感病毒血凝素（HA）蛋白，利用Moderna脂质纳米颗粒（LNP）递送系统，在体内表达HA抗原引发免疫应答。50-64岁获标准批准，≥65岁获加速批准（需上市后确证性研究）临床数据：基于III期FLUENT研究（NCT06602024），随机、观察者盲法、活性对照、病例驱动设计，入组40,703例≥50岁成人。主要终点：RT-PCR确诊流感样疾病的相对疫苗效力，mFLUSIVA相对标准剂量流感疫苗显示约26.6%的相对效力提升（达到非劣效性和优效性双重终点，数据发表于NEJM）。注射部位疼痛65.8%、疲劳45.1%、头痛37.8%，多为轻中度且短暂临床意义：全球首款基于mRNA技术的流感疫苗。审批过程跌宕起伏：2月CBER以对照组选择不当为由发出拒绝受理信（RTF），一周后在公众舆论压力下撤回决定接受修正申请，6月VRBPAC全票（9:0）推荐获批。mFLUSIVA成为Moderna继Spikevax、mRESVIA、mNEXSPIKE后在美第4款产品。但ACIP推荐时间和保险覆盖可能滞后，影响2026-2027流感季市场渗透率原文网址：https://www.pharmacytimes.com/view/fda-approves-mflusiva-the-first-mrna-based-influenza-vaccine
4. Pluvicto®扩展适应症——放射性配体疗法前移至转移性前列腺癌早期
批准日期：2026年8月3日持证商：Novartis适应症扩展：新增联合ARPI用于PSMA阳性转移性激素敏感性前列腺癌（mHSPC），此前仅获批用于mCRPC临床数据：基于III期PSMAddition研究。Pluvicto联合ARPI vs 单独ARPI，进展或死亡风险降低28%（首次分析）、33%（更新分析），OS趋势阳性但仍在成熟中临床意义：将Pluvicto从mCRPC后线治疗前移至mHSPC一线，** eligible患者群体几乎翻倍**。全球每年超18.6万例mHSPC新诊断，约半数20个月内进展为CRPC。80%以上前列腺癌患者PSMA阳性。Novartis已在美国运营或建设5个放射性配体疗法生产基地。精准放射治疗从后线走向一线的趋势加速原文网址：https://www.americanpharmaceuticalreview.com/Specialty/Formulation_Development/1315-News/627194-FDA-Approves-Pluvicto-for-Earlier-Stage-PSMA-Metastatic-Prostate-Cancer/
三、日本PMDA
本周（2026年8月3日-8月8日）日本PMDA无确认的新创新药获批信息。
注：据日本JIHO报道，武田oveporexton（ORZEYFUL）已在日本提交上市申请并获得优先审评，有望成为日本首个获批的NT1 orexin疗法。PMDA正加速审评流程。
四、欧盟EMA/EC
1. Jascayd™（nerandomilast）——欧盟获批用于IPF和PPF的口服PDE4B抑制剂
批准日期：2026年8月4日（EC授予上市许可）持证商：Boehringer Ingelheim适应症：特发性肺纤维化（IPF）和进展性肺纤维化（PPF）作用机制：口服磷酸二酯酶4B（PDE4B）选择性抑制剂。nerandomilast通过选择性抑制PDE4B，升高肺组织细胞内cAMP水平，发挥抗炎和抗纤维化双重作用。区别于已有PDE4抑制剂（如roflumilast），nerandomilast对PDE4B亚型具有更高选择性，旨在减少恶心等不良反应临床数据：基于FIBRONEER-IPF和FIBRONEER-ILD两项III期研究。事后汇总分析显示：nerandomilast 18mg BID vs 安慰剂，死亡风险降低43%（FIBRONEER-ILD亚群），9mg BID降低33%（FVC下降为主要终点已获FDA批准）。FDA已于2025年10月7日批准上市（IPF适应症），欧盟此次扩展覆盖PPF临床意义：肺纤维化领域重要进展。nerandomilast是首个同时覆盖IPF和PPF的口服抗纤维化药物，且事后分析提示生存获益。分析师认为其"开创了肺纤维化治疗的新篇章"。Boehringer Ingelheim在肺纤维化赛道持续深耕原文网址：https://www.thepharmaletter.com/regulation （2026年8月4日报道）
2. EMA CHMP 7月会议推荐12种新药获批
7月24日，EMA人用药品委员会（CHMP）在7月会议上推荐12种新药获批（含1个生物类似药和3个仿制药），待EC最终审批：
表格
药品名称活性成分适应症亮点Icotydeicotrokinra中重度斑块型银屑病（成人和≥12岁青少年）全球首个口服IL-23受体拮抗剂（此前IL-23靶向药均为注射生物制剂），已在美国获批（3月17日）Susvimoranibizumab湿性年龄相关性黄斑变性（wet AMD）欧盟首个可填充式眼内植入剂，手术植入一次后每6个月补充填充Lyrokaullerodalcibep高胆固醇血症每月一次皮下注射PCSK9抑制剂Evlarcoobicetrapib/ezetimibe高胆固醇血症/混合性血脂异常口服CETP抑制剂+依折麦布固定复方，LDL-C降幅可达63%Ubesloobicetrapib高胆固醇血症/混合性血脂异常口服CETP抑制剂单药Lynavoylinerixibat原发性胆汁性胆管炎相关严重瘙痒选择性胆汁酸转运蛋白（ASBT）抑制剂Nezglyalleriglitazone脑肾上腺脑白质营养不良（CALD）罕见儿童脑病，特殊情况下获批ZokoveaensitrelvirCOVID-19暴露后预防口服3CLpro抑制剂（此前已获批治疗适应症），扩展至暴露后预防Cavoleypegfilgrastim中性粒细胞减少症生物类似药
负面意见：KemSu（儿童急性疼痛）、Meplyffa（尼曼-匹克C型）、Qezzaqar（软组织肉瘤）未获推荐。
五、本周亮点
🌟 亮点一：Oreporexton开启orexin治疗新纪元——从症状管理到病因靶向
Takeda的oveporexton（Orzeyful）成为全球首个获批的orexin受体激动剂，标志着发作性睡病治疗范式的根本转变。此前全球没有任何药物获批用于NT1的整体治疗，患者只能同时使用兴奋剂控制嗜睡和羟丁酸钠控制猝倒。Oreporexton直接靶向orexin信号缺失这一根本病因，一次性覆盖日间嗜睡、猝倒、睡眠瘫痪、幻觉和夜间睡眠碎片化全部症状。更具里程碑意义的是，中国NMPA先于FDA全球首批该药，标志着中国在全球创新药审评速度上实现历史性突破。武田已布局后续orexin管线（TAK-360、TAK-495），orexin受体激动剂有望成为跨适应症的新治疗类别。
🌟 亮点二：Moderna mRNA流感疫苗获批——mRNA平台向呼吸道疾病全面扩展
全球首款mRNA流感疫苗mFLUSIVA获批，是mRNA技术继新冠疫苗后向常规季节性流感的重大扩展。审批过程一波三折：2月被CBER拒绝受理→一周后撤回决定→6月VRBPAC全票推荐→8月正式获批。III期FLUENT入组4万+例，相对标准剂量流感疫苗效力提升26.6%。50-64岁获标准批准，≥65岁获加速批准。这标志着mRNA技术平台从应急疫苗向常规疫苗的商业化转型正式起步，Moderna已形成覆盖新冠/RSV/流感的mRNA呼吸道病毒产品矩阵。但ACIP推荐和保险覆盖仍存不确定性。
🌟 亮点三：Tudriqev——溶瘤病毒"冷肿瘤转热"策略获FDA认可
Replimune的Tudriqev经历两次FDA拒绝后最终获批，验证了溶瘤病毒联合PD-1抗体克服免疫检查点耐药的策略。该药通过基因改造的HSV-1在肿瘤内选择性复制裂解癌细胞、释放抗原，联合nivolumab打破PD-1耐药壁垒。ORR 24.2%在PD-1耐药后的难治人群中具有临床意义，中位DOR达14.1个月。CTGTAC 10:3的投票结果反映了专家委员会对该临床价值的认可。分析师预计峰值销售13亿美元，体现了市场对这一创新机制的信心。
🌟 亮点四：Pluvicto前移至mHSPC——放射性配体疗法进入前列腺癌一线
Novartis将Pluvicto从mCRPC后线治疗前移至mHSPC一线，eligible患者群体近乎翻倍。PSMAddition III期数据显示进展或死亡风险降低33%。这一批准延续了放射性配体疗法（RLT）从后线走向一线的趋势，精准核医学在实体瘤中的定位持续强化。Novartis已在美国布局5个RLT生产基地，显示其对这一赛道的长期承诺。
六、本周重要申报/管线动态
表格
药品企业动态状态替恩戈替尼片（捷恩泰®）药捷安康NMPA附条件批准上市：FGFR2融合/重排晚期胆管癌（三线），ORR 28.0%，mPFS 6.0个月，mOS 20.7个月。此前获FDA孤儿药+快速通道、EMA孤儿药认定NMPA获批上市瑞康曲妥珠单抗（SHR-A1811）恒瑞医药NMPA获批HER2阳性结直肠癌新适应症（奥沙利铂/氟尿嘧啶/伊立替康治疗失败后），成为首款获批治疗结直肠癌的ADCNMPA获批艾玛昔替尼片恒瑞医药NMPA获批第五适应症：活动性放射学阴性中轴型脊柱关节炎（nr-axSpA）NMPA获批仑卡奈单抗皮下剂型卫材博鳌乐城先行区获批皮下自动注射剂型乐城先行区获批TQB3909片正大天晴全新结构BCL-2抑制剂，上市申请获CDE受理并纳入优先审评（基于II期数据申报）CDE优先审评中瑞康芦泽妥塔单抗（SHR-A2009）恒瑞医药HER3 ADC上市申请获CDE受理，拟用于EGFR突变晚期NSCLC（III期达主要终点）CDE审评中Risvuvatug Rezetecan（HS-20093）翰森制药B7-H3 ADC治疗骨肉瘤III期ARTEMIS-011研究达PFS主要终点（第二项成功的III期）拟申报上市Iberdomide百时美施贵宝CELMoD药物，复发/难治性多发性骨髓瘤NDA，PDUFA目标日8月17日，有望成为首个上市CELMoDFDA优先审评中Garetosmab再生元抗Activin A单抗，进行性骨化性纤维发育不良（FOP），基于III期OPTIMA（63例），新发异位骨化减少90-94%FDA优先审评中Pariglasgene brecaparvovec（DTX401）UltragenyxAAV8基因疗法，Ia型糖原贮积病（GSDIa），PDUFA目标日8月23日FDA优先审评中177Lu-edotreotide（ITM-11）ITM Isotope Technologies放射性配体疗法，GEP-NET，基于III期COMPETE研究，PDUFA目标日8月28日FDA优先审评中
七、数据来源
FDA Orzeyful批准公告：https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-treat-full-range-narcolepsy-type-1-symptomsTakeda Orzeyful获批新闻稿：https://www.takeda.com/en-us/newsroom/news-releases/2026/orzeyful-approved-narcolepsy/FDA Tudriqev批准公告：https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-vusolimogene-oderparepvec-wtpg-combination-nivolumab-melanomaFDA mFLUSIVA批准报道：https://www.pharmacytimes.com/view/fda-approves-mflusiva-the-first-mrna-based-influenza-vaccineFDA Pluvicto扩展适应症报道：https://www.americanpharmaceuticalreview.com/Specialty/Formulation_Development/1315-News/627194-FDA-Approves-Pluvicto-for-Earlier-Stage-PSMA-Metastatic-Prostate-Cancer/FDA Novel Drug Approvals 2026：https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026EMA CHMP 7月会议12种新药推荐：https://drugtodayonline.com/medical-news/news-topic/ema-backs-12-new-medicines-approvalsEMA CHMP 7月会议完整推荐列表：https://pharmacyupdateonline.com/2026/08/green-light-for-twelve-new-medicines-in-the-eu/EC Jascayd欧盟获批报道：https://www.thepharmaletter.com/regulation （2026年8月4日）EC MenQuadfi扩展适应症：https://www.thepharmaletter.com/regulation （2026年8月4日）药捷安康替恩戈替尼获批：http://m.toutiao.com/group/7670894482073584169/恒瑞瑞康曲妥珠单抗结直肠癌获批：https://m.weibo.cn/detail/5329353702644076全球创新药获批综合报道：http://m.toutiao.com/group/7671105560044978688/NMPA创新药品名录：https://www.nmpa.gov.cn/zhuanti/cxylqx/cxypxx/index.htmlPMDA官网：https://www.pmda.go.jp/index.htmlBiospace Approvals汇总：https://www.biospace.com/approvals?p=114
本期简报覆盖2026年8月3日至8月8日全球主要药品监管机构（NMPA/FDA/PMDA/EC）的创新药批准情况。仅收录创新药批准、重要新适应症/新剂型及First-in-Class/全球首创品种，不含普通仿制药和ANDA。NMPA创新药品名录更新存在延迟，本周部分批准信息来源于行业媒体报道，待官方公示后将补充确认。
优先审批抗体药物偶联物免疫疗法申请上市上市批准
100 项与 Respiratory Syncytial Virus Vaccine(Moderna) 相关的药物交易
登录后查看更多信息
研发状态
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 呼吸道合胞病毒肺炎 | 欧盟 | 2024-08-22 | |
| 呼吸道合胞病毒肺炎 | 冰岛 | 2024-08-22 | |
| 呼吸道合胞病毒肺炎 | 列支敦士登 | 2024-08-22 | |
| 呼吸道合胞病毒肺炎 | 挪威 | 2024-08-22 | |
| 下呼吸道感染 | 美国 | 2024-05-30 | |
| 呼吸道合胞体病毒感染 | 美国 | 2024-05-30 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 1,900 | mRNA-1345 RSV vaccine + quadrivalent influenza vaccine | 憲遞築壓構積範鹽顧簾(餘選簾憲鏇築夢繭鏇齋) = no deaths 繭築醖範糧壓構製築窪 (壓膚範廠襯鬱糧構構齋 ) 更多 | 积极 | 2026-12-01 | ||
临床3期 | 543 | 選願鏇淵觸鏇廠餘膚艱(鬱築範獵願網窪製繭遞) = 鑰網憲製餘鑰襯繭蓋餘 顧構構製範襯襯積衊餘 (壓艱繭鹽廠醖糧構製簾, 73.7 ~ 81.0) 更多 | 积极 | 2025-09-24 | |||
临床1期 | 46 | mRNA-1345 15 μg | 蓋鏇繭積蓋齋鹽鹽積鹹(願膚鬱觸膚憲襯觸壓壓) = 壓壓廠觸齋觸醖鑰選觸 淵範齋鹹襯積齋壓鑰範 (積顧選積觸醖獵壓構鬱, 27.3 ~ 50.0) 更多 | 积极 | 2025-09-15 | ||
mRNA-1345 30 μg | 蓋鏇繭積蓋齋鹽鹽積鹹(願膚鬱觸膚憲襯觸壓壓) = 願衊衊築衊夢齋願構網 淵範齋鹹襯積齋壓鑰範 (積顧選積觸醖獵壓構鬱, 53.3 ~ 71.4) 更多 | ||||||
临床3期 | 1,900 | Fluzone HD+mRNA-1345 (Fluzone HD + mRNA-1345 Followed by Placebo) | 積壓網觸鹹遞憲憲窪衊 = 製鏇蓋鑰製窪繭醖網積 觸鏇窪醖壓糧鏇製繭鏇 (積鏇衊夢齋廠壓鹹鏇鑰, 膚襯鹽餘壓蓋窪獵餘遞 ~ 膚繭鑰衊憲築顧衊壓襯) 更多 | - | 2025-07-30 | ||
Fluzone HD+mRNA-1345 (Fluzone HD + Placebo Followed by mRNA-1345) | 積壓網觸鹹遞憲憲窪衊 = 醖淵繭糧夢網齋製範鑰 觸鏇窪醖壓糧鏇製繭鏇 (積鏇衊夢齋廠壓鹹鏇鑰, 齋願夢膚餘繭壓網範遞 ~ 網憲蓋膚製醖襯鬱顧餘) 更多 | ||||||
临床2/3期 | - | - | mRNA-1345 RSV Vaccine (mRNA-1345 50-µg) | 範選衊衊襯糧齋構淵鏇(襯膚繭鹹積願遞簾廠觸) = 鏇鑰願蓋艱淵鹹遞願遞 齋鹹膚獵築顧構選窪獵 (醖憲積壓衊遞簾築觸廠 ) 更多 | 积极 | 2024-11-15 | |
临床1期 | 25 | 窪夢衊窪壓糧艱選襯壓(夢範築製鹽觸築醖夢衊) = 壓製積膚窪構齋蓋範夢 窪獵醖製窪蓋憲範顧襯 (繭鑰齋餘憲齋鏇廠選簾 ) 更多 | 积极 | 2024-09-09 | |||
安慰剂 | - | ||||||
临床2/3期 | 35,541 | 鹹願顧窪積廠觸窪獵網(選鬱壓製鏇廠鹹蓋鑰鹽) = 積淵廠範艱艱蓋艱觸願 膚願鏇願選獵襯淵製獵 (餘齋鬱窪簾餘鏇選繭壓, 66.0 ~ 92.2) 更多 | 积极 | 2023-12-14 | |||
Placebo | 衊憲網範網窪遞鏇顧艱(鏇襯鏇膚憲製鹹範壓積) = 衊網網膚築鬱蓋窪積鏇 鹽憲淵築積構鏇淵膚簾 (膚窪範顧範願繭淵網夢 ) | ||||||
临床3期 | 37,000 | 遞衊簾顧顧餘艱選廠鏇(鑰獵鏇築窪選顧網襯鏇) = 製繭鏇繭艱鏇築廠築築 糧網膚憲鑰簾選鏇艱鏇 (遞顧襯鹽築憲鹽膚壓繭, 66.1 ~ 92.2) 更多 | 积极 | 2023-08-03 | |||
临床3期 | 37,000 | 夢遞憲構鑰醖鑰憲糧鬱(壓簾簾憲鏇構網憲鹽齋) = 衊築鬱鹹網獵窪膚廠積 糧製艱願網糧夢窪構鏇 (鑰簾夢網蓋簾製憲遞願 ) 达到 更多 | 积极 | 2023-01-17 | |||
Placebo | 夢遞憲構鑰醖鑰憲糧鬱(壓簾簾憲鏇構網憲鹽齋) = 觸醖憲膚窪獵糧壓憲壓 糧製艱願網糧夢窪構鏇 (鑰簾夢網蓋簾製憲遞願 ) 达到 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
提出任何生物医药研究问题
让每一步生物医药决策都精准制胜
基于十亿级生物数据与全球情报的精准 AI，赋能早期药物发现
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即接入生物医药数据包
智慧芽新药库数据也通过智慧芽开放平台，以MCP或API服务形式对外开放。立即使用我们的MCP服务定制您的LLM智能体。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用